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Pulmonary hypertension (PH) is a condition where the pulmonary artery pressure is 
elevated. This condition develops due to various known and unknown factors. Pulmonary 
vascular constriction due to hypoxia or other factors give rise to acute pulmonary 
hypertension whereas progressive pulmonary vascular remodeling is more prominent 
feature in the chronic form of this disease. To simplify the diagnosis and treatment of PH, 
the disease has been classified into various groups according to its etiology. Among various 
factors, obesity has also been linked with pulmonary hypertension. Obesity, a condition 
where excess of adipose tissue accumulates in the body, exerts oxidative stress and 
inflammation in the body tissues. Since both important features of obesity, such as 
oxidative stress and increased inflammation, play a role in the pathophysiology of 
pulmonary hypertension, it has been speculated that obesity might contribute to the 
initiation, propagation or exacerbation of pulmonary hypertension. 
 
Obesity is prevalent in many countries. It is alarmingly increasing due to food processing 
as well as change of life styles. Obesity itself is associated with myriad of morbid states in 
heart such as hypertension, obstructive sleep apnea, obesity hypoventilation syndrome, 
coronary heart disease, heart failure, diabetes and insulin resistance. Nevertheless, research 
till date does not provide an explicit correlation between pulmonary hypertension and 
obesity. Conversely, some cohort studies have even shown beneficial effects of increased 
body weight in long term mortality due to pulmonary hypertension. However, proper 
research and convincing results are still missing in these circumstances.  
 
With these interesting but still unresolved issue, the present work aims to unveil the 
mechanisms and proper relationship between obesity and pulmonary hypertension. The 
results and conclusion obtained from this study may help to understand the underlying 
mechanisms and potential link of obesity and pulmonary hypertension. It may also open the 
door to find out the right therapeutic option in pulmonary hypertension patients who also 





Pulmonary hypertension (PH) and obesity are two obstinate diseases that may coexist in 
clinical practice. Intromitted by the disturbances of several molecular pathways, PH is 
characterized by increased vascular cell growth and inflammation culminating to right 
heart failure and death (Simonneau et al., 2013; Schermuly et al., 2011). Obesity, on the 
other hand, is a condition of excessive fat accumulation in the body, which has an 
established association with cardiovascular diseases, diabetes, renal dysfunction and 
several pulmonary disorders namely chronic obstructive pulmonary disease (COPD), sleep 
apnea and pulmonary embolism (Irwin et al., 2014). Although obesity has a long-familiar 
positive correlation with systemic hypertension, there are insufficient data with regard to 
obesity as a potential player for PH (Summer et al., 2012).  
 
The degree of adiposity of all levels has been alarmingly increasing in most part of the 
world. In spite of the fact that overweight and obesity predispose many cardiovascular 
diseases namely systemic hypertension, heart failure and coronary heart disease, the 
"obesity paradox" exists, which shows significant higher short or long term survival in 
obese patients than their lean counterparts (Lavie et al., 2014). Till date, no data have been 
able to show an effective role of obesity in PH. These studies are clearly missing and 
therefore this research is targeted to understand and find the proper correlation and 
molecular link between obesity and PH.  
 
Once thought to be a predominant female oriented disease in relatively younger age, the 
recent results on pulmonary arterial hypertension (PAH) suggest a more even ratio of male 
to female (Hoeper et al., 2013). Therefore, the current thesis also aims to unravel the 
important but not fully understood arena of female obesity in relation to PH in a murine 
model of male and female obesity. Surprisingly, in humans, the survival rate of females 
after the diagnosis of PH is shown to be higher than in males (Austin et al., 2013). 
Presuming the uniqueness of female hormones and physiology versus male, diversity of 
etiology and pathomechanism of PH, it would be crucial and exciting to explore the 
potential gender specific association of PH.  
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1.1 Pulmonary circulation 
 
The pulmonary circulation, along with systemic circulation and lymphatic circulation, is a 
part of the circulatory system. The pulmonary circulation comprises heart, pulmonary 
arteries and veins, and lungs. The pulmonary artery receives the deoxygenated blood from 
the right ventricle. It then transfers blood to the pulmonary capillaries via the artery 
network system where the oxygen exchange takes place. The oxygenated blood is pumped 
back to the left ventricle via the pulmonary veins from where it is distributed to the 
systemic circulation (Guyton and Hall, 2006). 
 
Various cardio-pulmonary diseases are related to abnormalities in the pulmonary 
circulation. Pulmonary hypertension is a medical condition where abnormally higher 
pulmonary artery pressure is seen due to various factors. Key parts are disturbed 
mitochondrial functions, inflammation and disordered growth factors which may or may 
not be genetically acquired. The structure and the function of the right ventricle plays an 
important role for the patient survival (Tuder et al., 2013). Hence, the diagnosis and 
treatment of diseases related to pulmonary circulation needs research focus not only on the 
lung but also on the heart. Especially, underlying genetic, epigenetic as well as molecular 
mechanisms have to be examined (Vonk-Noordegraaf et al., 2013).  
 
1.2 Anatomy and physiology of heart and lung 
 
Structure and function of heart and lung constitute the cardio-pulmonary system (Fig. 1). 
The heart is a muscular four chambered organ consisting of two each - atria and ventricles. 
Atria (singular: atrium) and ventricles are separated into right and left parts by interatrial 
and interventricular septum, respectively. The heart tissue consists of three layers - epi-, 
myo- and endo-cardium. It is protected by an outer double layered pericardium (Scanlon 
and Sanders, 2007). The right atrium first collects the deoxygenated blood and then 
transfers it to the right ventricle via tricuspid valve. The right ventricle then ejects the blood 
towards the lungs via pulmonary artery. The left atrium collects the oxygenated blood and 
forwards to the left ventricle via bicuspid / mitral valve, where the left ventricle pumps the 
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blood into the systemic circulation through the aorta. This whole process is initiated by the 
generation of electric impulses from the sino-atrial node (SA node). The excitation is 
conducted via the cardiomyocytes to the atrioventricular node. This node functions as a 
"bodyguard" and forwards only a certain amount of impulses. These continue their way 
through the Tawara's branches and finally reach the chamber myocardium via purkinje 
fibers. An electromechanical coupling generates the transduction from the electronic 
impulses into mechanical movement of the heart muscle (Guyton and Hall, 2006). 
 
 
Fig. 1: Schematic diagram of the cardio-pulmonary system. PA = pulmonary artery, PV = 
pulmonary vein, RA = right atrium, LA = left atrium, RV = right ventricle, LV = left ventricle 
 
In humans, the lungs are situated inside the thoracic cavity and are divided into right and 
left lungs. The right and left lungs are further divided into three and two lobes respectively. 
The heart lies in the mediastinum between the right and left lung. The cardiac notch in the 
left lung accommodates the pericardium. With a tremendous architectural design, the lungs 
consist of around 480 million gas exchange units - the alveoli, putting the total area for gas 
exchange to a huge 130 square meters. Maintained by primarily two types, type I and type 
II alveolar cells, the majority of the alveolar wall is covered by type I cells. These are able 




The spatial pattern and distribution of alveoli makes the lung a very sophisticated organ for 
the gas exchange. The internal lining of the airways is covered with epithelial cells which 
not only give physical protection to outside pathogen or foreign particles, but also assist by 
releasing antimicrobials and inflammatory mediators as well as recruiting immune cells. 
Other cell types, such as basal cells and clara cells also have adequate potentiality to 
proliferate and self regenerate into various cell types. This become important when external 
damage occurs in the epithelium (Tam et al., 2011). In addition to various protective 
functions such as detoxification, inflammation control, mucociliary clearance and 
maintenance of ciliated epithelial cells, clara cells also secrete surfactant proteins, 
cytokines, chemokines, antimicrobials and mucins (Reynolds and Malkinson, 2010).  
 
Although advancements in the knowledge and understanding of the cardio-vascular system 
have taken a long stride, the knowledge about the pathomechanisms behind pulmonary 
hypertension and pulmonary vascular diseases are still progressing. A deeper 
understanding of the pathobiology of pulmonary hypertension with respect to its etiology is 
more than needed for an effective treatment with lower side effects to the patients in future. 
 
1.3 Pulmonary hypertension 
 
Pulmonary hypertension is the condition of increased blood pressure in the pulmonary 
artery and is characterized by morbid and gradual growth, progression and increased 
motility of pulmonary vascular smooth muscle cells (Dahal et al., 2010; Schermuly et al., 
2005). Clinically, PH is defined as the mean pulmonary artery pressure of greater or equal 
to 25 mm Hg measured at a resting condition and measured through right heart 
catheterization. Right heart catheterization is established as the "gold standard" for 
diagnosis of PH. An additional measurement of pulmonary artery wedge pressure (PAWP) 
or pulmonary artery capillary pressure (PACP) is performed during the right heart 







Fig. 2: Schematic diagram showing increased thickness of pulmonary vessels and loss of cross 
sectional area. 
 
Associated with an acute form of vasoconstriction or a chronic phase of pulmonary 
vascular remodeling, PH results in the decrement of cross-sectional area of the vascular 
lumen, thereby increasing the right ventricle afterload. The abnormal pulmonary vascular 
remodeling is observed in all the three layers of the vessels - intima, media and adventitia. 
A decrease in the content/functions of various vasodilatory molecules such as 
prostaglandin I2 or nitric oxide and an increase in vasoconstrictive mediators such as 
thromboxane, serotonin and endothelin I, increase of growth factors such as vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), transforming 
growth factor - beta (TGF-β), platelet derived growth factor (PDGF), as well as 
involvement of inflammatory mediators, monocytes, macrophages, mast cells and disturbed 
cytokine and chemokine profiles play role in the development and patho-mechanism of PH 






Fig. 3: Severe histo-pathological features of the pulmonary vasculature found in the patients 
with pulmonary arterial hypertension (PAH). Neointima formation (B, E; indicated by black 
arrows) and plexiform lesions (C, F; indicated by red arrows), in comparison to the normal vessels 
(A, D). A, B, C: Elastica van Gieson staining; D, E, F: immunohistochemical staining (α-smooth 
muscle actin (violet color) and von Willebrand factor (brown color)). Scale bars = 20 µm. (Used 
with permission from the dissertation of Dr. Djuro Kosanovic (2011)). 
 
With all the changes in pulmonary artery remodeling, pulmonary hypertension leads to 
increased right heart afterload with compensatory mechanisms. However, the 
compensatory mechanisms become gradually insufficient giving rise to right ventricle (RV) 
failure. This RV failure ultimately determines the prognosis of patients (Vonk-Noordegraaf 
et al., 2013). Largely endorsed by symptomatic care, an effective and optimized treatment 
for pulmonary hypertension is still missing (Ghofrani et al., 2009).   
 
1.4 Updated classification of pulmonary hypertension 
 
To possess a common attribute for the characteristics and management of PH, clinical 
classifications have been made since 1998 in World Symposium on PH held in Evian, 
France. This classification has been updated with the advancement of knowledge in the 
pathobiology of this disease. The latest clinical classification of PH, which includes some 
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modifications and updates from the previous versions, comes from the 5th World 
Symposium held in 2013 in Nice, France. Based on the etiology, PH is classified into five 
groups. The first group include PAH with various causes, pulmonary veno-occlusive 
disease and/or pulmonary capillary hemangiomatosis and persistent PH of the newborn. 
The second group consists of PH due to left heart disease. PH due to lung diseases and/or 
hypoxia is included in the third group. The fourth and fifth group comprise the chronic 
thromboembolic PH and PH with unclear multifactorial mechanisms respectively. The 
classification is presented in the table (Simonneau et al., 2013). 
 
1.    Pulmonary arterial hypertension 
Idiopathic PAH 
Heritable PA:  
BMPR2 
ALK-1, ENG, SMAD9, CAV1, KCNK3 
Unknown 
Drug and toxin induced 
Associated with:  
Connective tissue disease 
HIV infection 
Portal hypertension 
Congenital heart disease 
Schistosomiasis  
1'.   Pulmonary veno-occlusive disease and/or pulmonary capillary 
hemangiomatosis 
1''.  Persistent PH of the newborn  
2.    Pulmonary hypertension due to left heart disease 
Left ventricular systolic dysfunction 
Left ventricular diastolic dysfunction 
Valvular disease 
Congenital/acquired left heart inflow/outflow tract obstruction and congenital 
cardiomyopathies 
3.    Pulmonary hypertension due to lung diseases and/or hypoxia 
Chronic obstructive pulmonary disease 
Interstitial lung disease 
Other pulmonary diseases with mixed restrictive and obstructive pattern 
Sleep-disordered breathing 
Alveolar hypoventilation disorders 
Chronic exposure to high altitude 
Developmental lung diseases 
4.    Chronic thromboembolic pulmonary hypertension 
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5.    Pulmonary hypertension with unclear multi-factorial mechanisms 
Hematologic disorders: chronic hemolytic anemia, myeloproliferative 
disorders, splenectomy 
Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
lymphangioleiomyomatosis 
Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid 
disorders 
Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure,  
segmental PH 
 
Table 1: Updated clinical classification of pulmonary hypertension as adopted by the 5th world 
symposium on pulmonary hypertension, Nice, France, 2013 (Simonneau et al., 2013). 
 
1.5 Current treatment for pulmonary hypertension 
 
With limited therapeutic options in the past, the evolution of treatment algorithms for 
pulmonary hypertension have advanced. At present, the main focus on the treatment relies 
on several areas such as rehabilitation and exercise training, application of drugs approved 
by the respective countries and the response and adjustments to the applied therapies (Galie 
et al., 2013). Currently, the main treatment regimes for pulmonary arterial hypertension and 
pulmonary hypertension relies on the endothelin receptor antagonists (such as ambrisentan, 
bosentan and macitentan) (Galie et al., 2013)., nitric oxide and prostacyclin pathways (such 
as selexipag) (Sitbon et al., 2015). Research on additional pathways has also allowed to 
utilize the tyrosine kinase inhibitors, Rho kinase inhibitors and serotonin receptor blockers 
for the potential future treatment of pulmonary hypertension (Dahal et al., 2010; Pulido et 
al., 2016).      
 
Soluble guanylate cyclase stimulators such as riociguat have been shown to significantly 
improve the 6 minute walk distance, pulmonary vascular resistance as well as WHO 
functional class in both naive pulmonary arterial hypertension patients as well as those who 
were receiving endothelin receptor antagonists (Ghofrani et al., 2013). Sildenafil, a 
phosphodiesterase 5 inhibitor (PDE5 inhibitor) has shown efficacy in the treatment of lung 
fibrosis, pulmonary arterial hypertension as well as portopulmonary hypertension. PDE5 
inhibitors works by acting on the nitric oxide and cyclic guanosine monophosphate 
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(cGMP) pathways thereby increasing the cGMP levels and exerting vasodilatory and 
antiproliferative effects (Ghofrani et al., 2004; Ghofrani et al., 2002; Reichenberger et al., 
2006).  
 
The complexity and patient response has lead to combination therapy with more than one 
classes of medicine with additional supports such as rehabilitation, exercise training or 
oxygen therapy to maintain the correct arterial blood oxygen pressure. 
 
1.6 Role of inflammation and oxidative stress in pulmonary hypertension 
 
Intensive research in the past years clearly suggested that increased inflammation plays a 
role both in experimental and clinical forms of pulmonary hypertension (Dahal et al., 2011; 
Kosanovic et al., 2014; Pullamsetti et al., 2011; Savai et al., 2012). Imbalance of serum 
cytokines in a study done in idiopathic and familial PAH patients indicated the 
involvement of a wide range of inflammatory mediators in PH (Soon et al., 2010).  
 
Furthermore, a significant increase of CD68 +ve macrophages, CD14+ve 
macrophages/monocytes, mast cells, CD209 +ve dendritic cells, CD3 +ve T cells, CD8 +ve 
cytotoxic T cells and CD4 +ve helper T cells were found in perivascular regions of various 
vascular categories (20-50 µm, 51-150 µm and > 150 µm) in the lungs of idiopathic PAH 
patients compared to that of healthy controls. This apparently suggests an altered 
infiltration and distribution of various inflammatory cells in PAH (Savai et al., 2012). In 
agreement to these findings, mast cells were also shown to be upregulated in the 
perivascular regions of the lungs of PH patients (Dahal et al, 2011; Kosanovic et al., 2014). 
Likewise, interleukin-6 is involved in the regulation of pulmonary arterial hypertension 
rendering the possibility to treat idiopathic pulmonary hypertension by intervening with 
this pathway (Furuya et al., 2010). The cytokines - tumor necrosis factor-alpha (TNF-α) 
and monocyte chemoattractant protein-1 (MCP-1) are also associated with pulmonary 
arterial hypertension and their interference allow beneficial effects in experimental 
monocrotaline model of PH in rats (Ikeda et al., 2004; Itoh et al., 2006; Wang et al., 2013). 
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These data further strengthen the fact of the involvement of inflammatory mediators in 
pulmonary hypertension (Fig. 4). 
 
Along with inflammation and inflammatory mediators, to check the presence of oxidative 
stress in the lung tissues of patients with severe PH, Bowers et al. measured and 
demonstrated elevated levels of nitrotyrosine and 5-oxo-eicosatetraenoic acid. This study 
suggested that the lung tissues of patients with severe PH are under oxidative stress 
(Bowers et al., 2004). The group of Peter Dorfmüller also presented a novel idea of 
immunologic responses to oxidative stress in experimental pulmonary hypertension 
associating the influx of oxidative stress causing mast cells and dendritic cells to the 
affected vascular regions in the lungs (Dorfmüller et al., 2011). Ellagic acid, a compound 
with anti-oxidative, anti-inflammatory and anti-proliferative properties effectively 
improved the monocrotaline induced pulmonary hypertension in rats suggesting the 
involvement of inflammatory pathways in this disease (Tang et al., 2014).  
 
In patients with an active pulmonary arterial hypertension, a controlled and non-
randomized clinical research has shown the presence of inflammation and oxidative stress 
supported by increase in lipid peroxidation, reduced glutathione and vitamin E (Reis et al., 
2013). Also, the treatment with chronic prostacyclin infusion showed anti-inflammatory 
effects in patients with severe pulmonary hypertension (Bowers et al., 2004). Inflammatory 
cells are known to produce metabolites of arachidonic acid, cytokines and chemokines, 
which further trigger the recruitment of inflammatory cells at the damaged site along with 
the production of more reactive species, thus playing a role in oxidative stress-induced 
inflammation (Reuter et al., 2010). 
 
The findings on clinical or experimental pulmonary hypertension of different origins 
suggest a certain involvement of inflammation and oxidative stress in the pathology of the 
disease (Bowers et al., 2004; Dahal et al., 2011; Musaad and Haynes 2007). Therefore, 
anti-inflammatory drugs may show beneficial effects and represent future targets for the 







Fig. 4: Schematic diagram showing the role of inflammation in PAH and the types of cells involved.  
 
1.7 Animal models of pulmonary hypertension 
 
Animal models have long been used to mimic human disease. Both large animals and small 
animals have been used for the research purposes. However, choosing small mammals such 
as mice, rats and guinea pigs makes it much easier for the researcher in terms of space, 
money, maintenance as well as handling. Use of animals in studies make sure that humans 
are safe but yet able to learn and investigate the most important diseases which otherwise 
would not be possible.  
 
Although some of the models employing rats and mice depict certain features common to 
human form of pulmonary hypertension, none of the animal models can precisely mimic 
the human conditions (Schermuly et al., 2011). Various models from environmentally or 
toxically induced models, as well as genetically modified models are currently used as 
models for pulmonary hypertension. Hypoxia induced pulmonary hypertension in mice, 
monocrotaline induced pulmonary hypertension in rats, bone morphogenetic protein 
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receptor 2 knockout mice, over-expressing interleukin 6 mice, cigarette smoke exposure, 
bleomycin induced pulmonary hypertension, pulmonary artery banding, transverse aortic 
constriction are some of the popular and successfully implied models for pulmonary 
hypertension (Pak et al., 2010). 
 
Many essential pathological characteristics of pulmonary hypertension can be revealed by 
smaller animal models. However, certain types such as persistent pulmonary hypertension 
of the newborn are best suited in comparatively larger ovine and swine animal models. 
Although difficult to manipulate, they have a distinct advantage of handling larger 
instruments or later collecting ample amount of tissues (Steinhorn, 2010). Likewise, certain 
congenitally acquired left to right shunting induced pulmonary hypertension is best 
described by chronic systemic to pulmonary shunting in piglets. This animal model 
recapitulates naturalistic features of pulmonary hypertension in few months which may 
require decades in humans to be noticeable (Dewachter and Naeije, 2010). As such, animal 
models are need to be chosen very carefully and pragmatically according to the type and 
pathology of the disease. Two of the animal models used in the study are described in the 
following sections. 
 
1.7.1 Hypoxia induced pulmonary hypertension 
 
Hypoxia is a condition of reduced oxygen level in the tissues. People living or ascending 
high altitudes frequently experience lower oxygen pressure and may develop acute 
mountain sickness or PH. The lungs respond to hypoxia with a compensatory mechanism 
where pulmonary vasoconstriction occurs allowing to redistribute the pulmonary artery 
blood into the area where higher oxygen exchange capability is available. Known as von 
Euler-Liljestrand mechanism, this process of initial hypoxia adaptation, optimizes the 
oxygen exchange in the lungs (Sommer et al., 2008). 
 
A chronic hypoxia exposure for a longer time will eventually lead to complex molecular 
and cellular alterations in the lung vasculature that contributes for the proliferation and 
remodeling of the pulmonary vessels (Stenmark et al., 2006). Taking advantage of the same 
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effect, hypoxia models are widely and successfully used as a model of pulmonary 
hypertension with a very high reproducible rate, mostly rats and mice (Dahal et al., 2011; 
Dahal et al., 2010; Schermuly et al., 2005). Nevertheless, the hypoxia injury and 
remodeling varies between different species of animal models (Stenmark et al., 2009).  
 
Chronic hypoxia in rats and mice acquire mild to moderate type of pulmonary hypertension 
and do not represent the complex manifestation as that of human forms. It is crucial to 
indicate that the classical chronic exposure of mice and rats basically mimics the group 3 of 
the current clinical classification of PH. To overcome this problem and to find closer model 
for PAH (group 1), a combination of different factors are applied to achieve the best 
representation of the disease. SU5416 (3-[(2,4-dimethylpyrrol-5-yl) methylidenyl]-indolin-
2-one), a synthetic vascular endothelial growth factor receptor (VEGFR) - 2 inhibitor, in 
combination with chronic hypoxia, has been shown to manifest severe pulmonary 
hypertension in rats. The establishment of this model ensured the appearance of pre-
capillary occlusion by the proliferation of endothelial cells which are also the 
characteristics of the human form (Taraseviciene-Stewart et al., 2001). SU5416, in 
combination with hypoxia, also show similar effects in mice and persists more than 10 
weeks after the return of normoxic conditions, albeit without further worsening of 
pulmonary hypertension or right ventricular dysfunction (Vitali et al., 2015).  
 
1.7.3 Monocrotaline induced pulmonary hypertension 
 
Monocrotaline is a pyrrolizidine alkaloid commonly found in many species of the 
Crotalaria plant and it is toxic to birds and mammals. Administration of monocrotaline in 
rats causes a cascade of events resulting in a severe form of pulmonary hypertension 
(Wilson et al., 1992). The precise and accurate explanation for the mechanism of action of 
monocrotaline is still not clear, but it has been suggested that the drug after entering the 
liver, is converted into monocrotaline pyrrole form and after traveling the lung vasculature, 
causes injury to the endothelium, finally activating the pathways responsible for 
proliferation and remodeling of pulmonary vessels. Monocrotaline induced pulmonary 
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hypertension is clearly seen in rats, but its effects on mice appear meek showing species 
differences of toxicity from this toxin (Dumitrascu et al., 2008).   
 
Higher doses of subcutaneous monocrotaline injections show dose dependent toxicity and 
mortality in mice. Microscopic anatomy revealed severe interstitial pneumonia and lung 
fibrosis showing the advancement of disease in a non-reversible way indicating a possible 
model for lung cancers related to pulmonary fibrosis (Hayashi et al., 1995). Studies have 
also been done on cell cultures. Monocrotaline exposure to bovine pulmonary artery 
endothelial cells caused abnormal enlargement of cells characterized by enlarged Golgi, 
mislocalization of endothelial nitric oxide synthase and decreased nitric oxide indicating 
both Golgi and sub-cellular trafficking dysfunction (Lee et al., 2009). Study on human 
pulmonary arterial endothelial cells treated with monocrotaline pyrrole showed decreased 
expression of bone morphogenetic protein receptor II and transient expression of Smad 
(Suppressor of mothers against decapentaplegic) signaling pathways providing the 
evidence of resemblance to human pulmonary hypertension characteristics and the 
usefulness of this molecule in in-vitro model to exhibit molecular mechanism of pulmonary 
hypertension (Ramos et al., 2008).  
 
 
Fig. 5: Monocrotaline (Synonym: crotaline). Structure reconstructed from D. W. Wilson, Department 





The monocrotaline model is being widely used in rats as a model for pulmonary arterial 
hypertension and it represents a historical model used in our research group for years 
(Dahal et al., 2010; Kosanovic et al., 2011; Schermuly et al., 2005). Keeping in mind the 
complexity and versatility of pulmonary hypertension in humans, this model should be 
carefully used to depict the underlying mechanisms and interpretations should be made by 




Obesity is the condition of excessive accumulation of adipose tissue in the body. Generally 
estimated by means of body mass index, it gives an idea about the general condition. 
Obesity contributes myriads of adverse effects in the body such as psychological stress, 
insulin resistance, type II diabetes, leptin resistance, systemic hypertension, certain types of 
cancers and cardiovascular disease the deterioration of health condition and reduced life 
expectancy. The rate of obesity is alarmingly increasing and associated with numerous 
factors including sedentary life style, higher intake of processed and fast foods as well as 
genetic makeup (Yazdi et. al., 2015).  
 
Adipose tissue is a loose connective tissue regarded as an endocrine organs due to fact that 
it secretes a wide range of adipokines as well as pro- and anti-inflammatory mediators such 
as leptin, adiponectin, interleukin-1 beta, interleukin-10 and tumor necrosis factor. Increase 
in adipose tissue or obesity leads to disorganization of these hormones or proteins with a 
variety of complications for example adverse effects on hemodynamics and cardiovascular 
structure and function, chronic inflammation, reduced insulin sensitivity, pre-diabetes and 
lower adiponectin levels. These effects due to obesity warrants complex metabolic 
syndrome (Grant and Dixit, 2015; Lavie, Milani, and Ventura, 2009).  
 
Recently, it has also been suggested that the obesity related co-morbidities are different in 
obese subjects depending upon whether they are responders or non-responders indicating a 
biological variance within the obese groups. Interestingly, similar pattern are also seen in 
the lean counterparts in terms of metabolic diseases, where the two groups respond in a 
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dissimilar manner (Grant and Dixit, 2015). Elucidation on these variations in cellular and 
molecular levels would resolve many findings and provide insights on the involvedness of 
obesity with its associated morbidities.  
 
Various obese models of rats and mice are available for obesity research. The models can 
either be genetically prone to obesity or special food diets higher in total fat percentage can 
be given to induce obesity. 
Male and female obesity also have different characteristics and processes for deposition of 
adipose tissues in the body and it has been deemed important to include both sexes in basic 
research or clinical trials. Males have the tendency to accumulate more adipose tissues in 
the visceral region, while females conglomerate in the subcutaneous region (Palmer and 
Clegg, 2015). An experiment with high fat fed diet induced obesity presented the 
dimorphism of the increase in left ventricular mass in mice. This left ventricular mass was 
significantly higher in the male mice (Böhm et al., 2013). A nationwide study in United 
Sates of America showed that female patients had higher asthma prevalence than male in 
class III obesity (Wang et al., 2015). These data suggest that male versus female obesity 
may have different physiological features and pathologies. 
 
1.8.1 Body mass index as a measure for obesity 
 
Body mass index (BMI) is a system to measure the degree of obesity. It is calculated by 
dividing the weight in kilogram by the height square in meter. It is accepted worldwide 
with some differences between the countries. The calculation of BMI requires only height 
and weight, so its calculation can be easily done. Because BMI does not consider factors 
like the type and location of tissues or fat within the body, it is only used for screening and 
not for the diagnostic value (http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/, 







International BMI calculation for adults given by world health organization (WHO): 
 
Body mass index (Kg/m
2
) Status 
< 18.5 Under-weight 
18.5 - 24.99 Normal weight 
25.0 - 29.99 Overweight / Pre-obese 
30.0 - 34.99 Class I obesity 
35.0 - 39.99 Class II obesity 
> 40.0 Class III obesity 
 
Table 2: Classification of adult obesity. (http://apps.who.int/bmi/index.jsp?introPage=intro_3.html, 
retrieved on 18 Feb, 2016) 
 
Determining the body mass index for infants, toddlers and teenagers are different than 
those of adults. Suggestions for the body mass index chart for different age groups have 
also been made which will assist in the tracking and advising for the weight balance during 
the different growth periods. These kind of charts might also bring a way for body mass 
index screening for necessary adjustment in children and adults (Elizabeth and 
Muraleedharan, 2003).  
 
The body mass index in rodents are usually calculated as weight in gram divided by length 
square in centimeter (gm/cm
2
). Length is measured from the tip of nose to the base of tail. 
 
1.10 Current understanding of obesity in pulmonary hypertension 
 
The evidence up to date is not sufficient to relate obesity and pulmonary hypertension 
thoroughly. The frequency of patients with pulmonary hypertension and co-morbidity such 
as obesity is increasing (Poms et al., 2013). However, long term statistical studies have 
shown either less risk of death or low mortality of obese pulmonary hypertension patients 
(Badri et al., 2012; Poms et al., 2013; Zafrir et al., 2013). Whether or not obesity has direct 




Obesity also is one of the many causes for leptin resistance. Leptin which is secreted by the 
adipose tissue is a key hormone for energy regulation (Banks et al., 2004; Berbari et al., 
2013). With an adjustment to obesity or body mass index, pulmonary arterial hypertension 
patients with high leptin levels have higher survival rates and lower leptin levels are linked 
with high mortality (Tonelli et al., 2012). Ghrelin, another hormone related to energy 
regulation, also stimulates adiposity in experimental conditions (Tschöp et al., 2000) 
suggesting that impairment of these energy regulating hormones might play a role in the 
development of pulmonary hypertension. 
 
Obesity expresses the possibility of developing the conditions of obesity hypoventilation 
syndrome (Kauppert et al., 2013) and obstructive sleep apnea (Vgontzas et al., 2000) which 
are more concerning and intriguing disease sequela. The formal classification of PH also 
lists sleep disordered breathing and alveolar hypoventilation disorder as possible etiology 
of pulmonary hypertension (Simonneau et al., 2013). Also the data from pulmonary 
hypertension arising due to obstructive sleep apnea or obesity hypoventilation syndrome 
suggest that these patients only suffer from mild to moderate form of the disease (Kauppert 
et al., 2013; Kessler et al., 1996). This milder form of disease may explain the obesity 
paradox where less mortality of obese patients is seen after the first diagnosis.  
 
Adiponectin, an anti-inflammatory cytokine, secreted primarily by adipose tissues, is 
down-regulated in various clinical conditions such as pulmonary hypertension, type II 
diabetes, insulin resistance, obesity, coronary artery disease or other cardiovascular 
diseases (Li et al., 2007; Medoff et al., 2009; Summer et al., 2009). Adiponectin through its 
beneficial effects on pulmonary artery smooth muscle cells, is shown to inhibit the 
remodeling process in the context of pulmonary hypertension (Weng et al., 2011). The role 
of adiponectin has also been demonstrated in lung injury and inflammation in adiponectin 
deleted mice model (Konter et al., 2012). Therefore, adiponectin, due to similar alteration 
pattern in both obesity and pulmonary hypertension, may represent a potential link between 




Another evidenced pathway for adiponectin is the suppression of C-reactive protein from 
the endothelial cells. Adiponectin also inhibits the activity of nuclear factor-κB (nuclear 
factor kappa-light-chain-enhancer of activated B cells) (Devaraj et al., 2008). Higher 
expression of C-reactive protein and nuclear factor-κB are related to obesity and 
cardiovascular abnormalities with higher expression of interleukins and cell adhesion 
mediates (Devaraj et al., 2008; Ouchi and Walsh, 2008). This higher levels of interleukins 
leads to vasoconstriction by inhibiting eNOS (endothelial nitric oxide synthase) pathway 
(Hansmann and Rabinovitch, 2010).  
 
In addition to pulmonary hypertension, adiponectin appears to be a common molecule 
which has been attributed to down-regulation of various clinical conditions such as 
diabetes, insulin resistance and obesity. It can be speculated that this exclusive molecule is 
the common factor which has the molecular connection between pulmonary hypertension 
and obesity, diabetes and insulin resistance. Nevertheless, proper evidences need to 
plausibly connect this interaction.  
 
Fat diet induced obesity in rats has also been shown to cause increased oxidative stress in 
the pulmonary artery wall, as well as elevated inflammatory cytokines in the blood plasma 
(Irwin et al., 2014). It has also been postulated that obesity might play crucial role in the 
pathobiology of pulmonary diseases through the involvement of pro-inflammatory 
mediators contributing a low grade systemic inflammation (Mancuso, 2010).  
 
Obese mice showed increased cardiac expression of prepro-endothelin-1 mRNA (micro 
ribonucleic acid), protein as well as endothelin receptors A and B mRNA compared to their 
lean counterparts (Catar et. al., 2014) suggesting that increase in adipose tissues can be 
important later for the disease development and its further complications. Importantly, the 
altered endothelin system is described in the context of PH (Kosanovic et al., 2011). 
 
Musaad and Haynes have elaborated the importance of obesity derived inflammation and 
oxidative stress in the tissues and organs of the body taking into account the environmental 
and genetic background of the subjects. Increase of adipose tissue mass leads to increased 
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levels of oxidized low density lipoprotein, IL-6, TNF-α and CRP as well as decrease in 
adiponectin levels, subsequently increasing the cardiovascular risk in general (Musaad and 
Haynes, 2007).  
 
Pulmonary hypertension, on the other hand, is also closely connected with chronic 
inflammatory processes with the infiltration of various inflammatory cells, such as mast 
cells, macrophages and dendritic cells. Increased expressions of pro-inflammatory 
cytokines and chemokines also contribute to the pulmonary vascular remodeling processes 
(Dahal et al., 2011; Pullamsetti et al., 2011; Savai et al., 2012). In addition, PH is indeed a 
disease which considers oxidative stress, as one of its features (Bowers et al., 2004).  
 
Therefore, the current understanding apparently suggests that both obesity and pulmonary 
hypertension are characterized by altered inflammation and oxidative stress, potentially 
showing a possible interaction between these two conditions (Fig. 6).  
 
Fig. 6: Schematic diagram for the obesity - pulmonary hypertension possible pathway. IL-6 = 
interleukin-6, TNF-α = tumor necrosis factor - alpha, MCP-1 = monocyte chemoattractant protein - 
1, Ang = angiotensinogen, F2 IsoPs = F2 isoprostanes, CRP = C-reactive protein, oxLDL = oxidized 
low density lipoprotein. (Neupane et. al., PVRI Chronicle, 2014) 
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1.11 Metabolic dysfunction, gender and endocrine players  
 
The metabolic activities within a normal cell or organ are tightly and precisely maintained. 
Cardiac dysfunction with altered metabolism and differences in nature and form of degree 
of progress in pulmonary hypertension has been shown with regard to gender, animal 
models and well as female sex hormones (Bal et al., 2013; Belke et al., 2000; Stevan et al., 
2009). Pulmonary hypertension in studies done decades before showed it to be primarily a 
female oriented (female : male :: 1.7 : 1) disease with only 10% of patients older than 60 
years (Ghamra and Dweik, 2003). However, a more recent result suggest that the course of 
pulmonary hypertension has been shifted to older patients (greater than 65 years) with 
almost even female to male ratio (female : male :: 1.2 : 1), although the ratio of female to 
male in young diagnosed patients were higher (Hoeper, Huscher, et al., 2013).  
 
Surprisingly, survival rates of females after diagnosis are higher (Austin et al., 2013). This 
asymmetrical characteristic of the disease has not been explained but the possibility of 
endocrine hormonal roles cannot be taken out. Experimentally induced monocrotaline 
model of pulmonary hypertension showed less severity of disease in female rats. Higher 
antioxidant defense capacity of female rats was thought to play the protective role (Bal et 
al., 2013). Protective effects of estrogen has been shown in monocrotaline model of 
pulmonary hypertension in female Sprague-Dawley rats and ovariectomized females were 
more prone to pulmonary hypertension (Yuan et al., 2013).  
 
Because of the diversity of etiology and patho-mechanism of pulmonary hypertension, a 










1.12 Hypothesis, objectives and aims of the study 
 
Therefore, based on the above mentioned knowledge and current understanding, the role or 
contribution of obesity to the pathogenesis of pulmonary hypertension is not accurately and 
profoundly described and systematic investigation is still missing. In the line with this 
thinking, I would like to hypothesize that increase in adipose tissue may represent an 
important factor of the patho-biology of pulmonary hypertension. 
 
Objectives and aims of the study are: 
 
 To investigate the role of obesity in development of experimental pulmonary 
hypertension, using two well-established models of the disease, such as 
monocrotaline (MCT)-induced pulmonary hypertension in rats and chronic 
hypoxia-induced pulmonary hypertension in mice. 
 
 To reveal the potential differences between male and female obesity in the context 
of pulmonary hypertension. 
 
Genetically modified obese male and female Zucker rats and their lean counterparts were 
used for the monocrotaline (MCT) model. Similarly, genetically modified obese male and 
female B6 mice and their lean counterparts were used for chronic hypoxia model. Invasive 
hemodynamic measurements, echocardiography and histological assessment were 
performed for measurement of right heart function and hypertrophy, hemodynamic 
parameters and pulmonary vascular remodeling. This study may reveal important details 
about potential involvement of obesity in experimental pulmonary hypertension and 












Table 3: Materials used for animal experiments, echocardiography, invasive 
hemodynamics and histology with semi-quantitative computer-based morphometry. 
Substance  Supplier 
Blood analyzer Rapid Lab 348 Siemens, Germany 
High-resolution imaging system 
VEVO 2100 
VisualSonics, Toronto, Canada 
Transducers B. Braun Melsungen, Melsungen, Germany 
SAR-830/P Ventilator IITH Life Science INC., CA, USA 
Isoflurane Forene
®
 Abbott, Wiesbach, Germany 
Braunoderm
®
 B. Braun Melsungen, Melsungen, Germany 




Parker Laboratories, Fairfield, NJ, USA 
Physiological saline solution DeltaSelect GmbH, Dreieich, Germany 
Heparin Ratiopharm GmbH, Germany 
Dexpanthenol eye ointment Bayer, Leverkusen, Germany 
Monocrotaline (Crotaline®) Sigma-Aldrich Biochemie GmbH, Steinheim, 
Germany 
Ketamin-10% Bela Pharm, Vechta, Germany 
Physiological saline solution B.Braun, Melsungen AG, Melsungen, Germany 
Xylazin 2%  Ceva Tiergesundheit, Dusseldorf, Germany 
Normoxic ventilation gas (21% O2, 
5.3% CO2, balanced with N2) 
Praxair, Germany 
Hypoxic ventilation gas (1% O2, 




 1mg/ml    Janssen Animal Health (Elanco) Bad Homburg, 
Germany 
Baytril 2.5% Bayer Leverkusen, Germany 
Veet shaving creme Bayer Leverkusen, Germany 
EDTA Monovette Sarstedt, Nümbrecht, Germany 
Automated microtome RH 2255 Leica Microsystems, Wetzlar, Germany 
Tissue embedding machine EG 
1150H 
Leica Microsystems, Wetzlar, Germany 
Sakura cassette printer Sakura finetek Germany 
Tissue dehydrating machine TP1050 Leica Microsystems, Wetzlar, Germany 
Cooling plate EG 1150 C Leica Microsystems, Wetzlar, Germany 
Flattening table HI 1220 Leica Microsystems, Wetzlar, Germany 
Flattening bath for paraffin sections 
HI 1210 
Leica Microsystems, Wetzlar, Germany 
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Hypoxic chambers Oxycycler Model 
A84XOV 
Bio Spherix, New York, USA 
Stereo light microscope DMLA 6000 Leica Microsystems, Wetzlar, Germany 
Imaging workstation Q550IW Leica Microsystems, Wetzlar, Germany 
Imaging software QWin V3 Leica Microsystems, Wetzlar, Germany 
Ethanol 70%, 95%, 99.6% Otto Fischar GmbH, Saarbrücken, Germany 
Coverslip Menzel, Germany 
2% acid fuchsin  
Avidin-Biotin blocking kit Vector, Wertheim-Bettingen, Germany 
DAB substrate kit Vector, Wertheim-Bettingen, Germany 
Dako Real
TM
 proteinase K  Dako, Glostrup, Denmark 
Eosin Y Thermo scientific, Kalamazoo, USA 
Formaldehyde 3.5 - 3.7%  Otto Fischar, Saarbrucken, Germany 
Haemalaun, Sauer nach Mayer Waldeck GmbH, Muenster, Germany 
Hydrogen peroxide 30% Merck, Darmstadt, Germany 
ImPRESS kit anti-rabbit Ig Vector, Wertheim-Bettingen, Germany 
Isopropanol (99.8%) Fluka Chemie, Buchs, Switzerland 
Methanol Sigma-Aldrich Biochemie GmbH, Steinheim, 
Germany 
Methyl green Vector, Wertheim-Bettingen, Germany 
Mounting medium (Pertex
®
) Medite GmbH, Burgdorf, Germany 
Mouse-on-mouse HRP polymer Biocare Medical, Concord, USA 
Normal horse serum Vector, Wertheim-Bettingen, Germany 
Normal rabbit serum Vector, Wertheim-Bettingen, Germany 
PAP pen Kisker Biotech, Steinfurt, Germany 
Paraplast plus Sigma Aldrich, Steinheim, Germany 
Trypsin Digest all 2
®
 Zytomed, Berlin, Germany 
Vector VIP substrate kit Vector, Wertheim-Bettingen, Germany 
Xylol Roth, Karlsruhe, Germany 
Glass slides (SuperFrost UltraPlus
®
) Langenbrinck, Emmendingen, Germany 
Embedding cassettes Leica Microsystems, Nussloch, Germany 
Microtom blades type A35 Feather Safety Razor Co. Ltd, Japan 
 
Antibodies for immunohistochemistry. 
Mouse anti-α-SMA, clone 1A4 
monoclonal 
Sigma Aldrich, Steinheim, Germany 
Rabbit anti-von Willebrand factor Dako Cytomation, Hamburg, Germany 
Mouse anti-Rat CD68 (MCA341R) AbD Serotec 
 
   
     




Napkins Tork, Mannheim, Germany 
Falcon tubes Greiner bio-one, Frickenhausen, Germany 
Single use gloves Microtouch Ansell Healthcare Europe, Brussels, Belgium 
Filter tips Filter tips 
Disposable feather scalpel Feather safety razor Co. Ltd, Osaka, Japan 
Pipette tips EPPENDORF, Hamburg, Germany 
Syringe Injekt®-F Braun, Melsungen, Germany 
Black thread no. 16 Coats GmbH, Kenzingen, Germany 
Medical adhesive bands (3M™ 
Durapore™ Surgical tape 
3M Health Care, St, Paul, MN, USA 
Gauze balls size 6 Fuhrmann Verrbandstoffe GmbH, Munich, 
Germany 
Surgical instruments Fine Science Tools GmbH, Heidelberg, 
Martin Medizintechnik, Tuttlingen, Germany 
Cannula for vein catheter support 
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B. Braun Melsungen AG, Melsungen 




2.2.1 Animal models 
 
Adult obese and lean male and female Zucker rats (Crl:ZUC-Lepr
fa)
 were obtained from 
Charles River Laboratories (Sulzfeld, Germany). Similarly, ob/ob B6.Cg-Lep
ob
/J obese and 
lean (C57BL6/J or B6) mice (male and female) were also obtained from Charles River. All 
animals were kept under controlled temperature (22 ± 2
o
C and a daylight/night cycle of 
14/10 hours with ad libitum food and water supply. The protocols were approved by the 
governmental Animal Ethics Committee: Regierungspraesidium Giessen, GI 20/10 Nr. 




       
 
Fig. 7: Lean and obese Zucker rats. Left: lean male Zucker rat, Right: obese male Zucker rat. 
 
 
2.2.2 Monocrotaline (MCT) induced pulmonary hypertension model in rats 
 
MCT model is well-established in our research group and it was used in this study, as we 
previously described and published (Dahal et al., 2011; Dahal et al., 2010; Dumitrascu et 
al., 2008; Kosanovic et al., 2011; Schermuly et al., 2004; Schermuly et al., 2005). 
Pulmonary hypertension in the Zucker rats was induced by single subcutaneous injection of 
monocrotaline with a dose of 60mg/kg body weight as described previously (Schermuly et 
al., 2005). Monocrotaline (MCT) solution was prepared by dissolving the Monocrotaline 
(Crotaline
®
) in 1N HCl and 1N NaOH and pH was maintained at 7.4. The MCT solution 
was injected at day 0 subcutaneously in the neck. These MCT injected rats received 2.5% 
Baytril (antibiotic) in drinking water from 1
st
 day to 15
th
 day. Baytril solution was prepared 
by mixing 2ml of Baytril in 500ml of drinking water. As a healthy control, Zucker rats 




2.2.3 Hypoxia induced pulmonary hypertension model in mice 
 
Pulmonary hypertension in B6 ob/ob was induced by exposing the mice to hypoxia (10% 
O2 fraction, FiO2 10%) in normobaric hypoxic chamber for 5 weeks, as we previously 
described (Schermuly et al., 2005; Dahal et al., 2010; Dahal et al., 2011). The control mice 
were placed in the similar condition but in normoxic chamber (21% O2 fraction, FiO2 
21%). The systems were regulated automatically to maintain the chamber normoxic and 
hypoxic. The procedure were similar for both male and female mice. 
 
2.2.3.1 Experimental design 
 
Experimental design for rats and mice is depicted below. 
 
 






Non-invasive measurement of several functional and morphometric parameters was 
performed by echocardiography, as we have previously described and published 
(Kojonazarov et al., 2013; Kosanovic et al., 2011; Savai et al., 2014). For this purpose, 
mouse or rat was anesthetized in the induction chamber supplied with 3% isoflurane in 
100% oxygen. After the animal lost its reflex action, it was taken out and kept in supine 
position on a heating platform. The limbs of the animal were taped to ECG electrodes and 
the anesthesia was maintained with 1.5% isoflurane in 100% O2 through a nose cone. The 
body temperature was monitored through a rectal probe. A dexpanthenol eye ointment 
(Bepanthen
®
) was applied in the eyes of animal to avoid their drying. A pre warmed 
ultrasound gel was applied over the chest wall after shaving the chest. Echocardiographic 
images were acquired with a VEVO2100 high resolution imaging system (Visual Sonics, 
Toronto, Canada) equipped with MicroScan linear array transducers MS550D (22-55 
MHz) and MS250 (13-24 MHz). Following parameters were analyzed: 
 
Right ventricle free wall thickness 
It is the measure of the thickness of the right ventricle free wall. It is measured in 
millimeter and serves as a parameter of the right ventricle hypertrophy. 
 
Right ventricle internal diameter 
This is the distance between the inner linings of right ventricle free wall to the inner linings 
of interventricular septum towards the right ventricle. It is measured in millimeter and 
serves as a parameter of the right ventricle hypertrophy and dilatation. 
 
Tricuspid annular plane systolic excursion (TAPSE) 
TAPSE is the distance covered by right ventricle annular plane towards the apex and serves 
as a parameter of right ventricle longitudinal function. It is measured in millimeter. The 
normal value of TAPSE in humans is greater than 16 mm and decreases in heart failure or 
pulmonary hypertension. TAPSE is considered as an effective prognostic value for the 
survival of patients suffering from pulmonary hypertension. The mortality in patients with 
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TAPSE greater than 18 mm were significantly lower than those where the value were less 
than 18 mm (Forfia et al., 2006).  
 
Pulmonary artery acceleration time (PAAT) / pulmonary artery ejection time (PAET) 
PAAT is the time from the onset to peak velocity of pulmonary  artery flow, obtained using 
pulsed wave Doppler echocardiography from the left parasternal short axis view. PAET is 
the full time required for the pulmonary outflow. The ratio of PAAT to PAET gives more 
reliable data because PAAT is dependent on heart rate. In humans, the normal heart rate is 
around 60-80 beats per minute, so the range is small. However, for small rodents, this 
range can be very high, even up to a difference of 200 beats per minute. 
 
Cardiac output 
It is the volume of blood ejected from the left ventricle or right ventricle into the circulation 
each minute. Cardiac output equals stroke volume, the volume of the blood ejected by the 
ventricle during each contraction, multiplied by the heart rate, the number of heart beats per 
minute. It can be calculated by the following formula: 
CO = HR x SV, where CO = cardiac output, HR = heart rate, SV = stroke volume 
The unit of measurement is liters/minute in humans and milliliters/minute in rodents. 
 
Cardiac index 
It is the ratio of cardiac output per unit area of the body. It estimates the performance to 
heart or the cardiac output according to the size of the body. Cardiac index can be 
calculated by the following formula: 
CI = CO / BSA, where CI = cardiac index, CO = cardiac output, BSA = body surface area. 
The unit of measurement is liters per minute per square meter in humans. In rodents, the 
cardiac index is given as cardiac output relative to body weight (milliliters/minute/gram 






2.2.5 Hemodynamic measurements 
 
The hemodynamic measurements were performed in full agreement and following the 
protocol that we have previously described and published (Dahal et al., 2011; Dahal et al., 
2010; Kosanovic et al., 2011; Schermuly et al., 2005). Rats were anesthetized by 
intraperitoneal injection of combination of ketamine and domitor solution in the ratio of 
10:1. The anesthetized animal was placed in supine position and neck and chest area were 
cleaned with Braunoderm
®
. After that the tracheotomy was performed and animal was 
artificially ventilated with a mixture of oxygen and nitrogen in the ratio 1:1 at a frequency 
of 60 breaths/min with an inspiratory flow rate of 500-600cc/min. The left carotid artery 
was isolated and small incision was made. To prevent blood coagulation, 0.5ml of heparin 
solution was administered. A cannula connected to a fluid filled transducer was inserted 
through the incision and systemic arterial pressure (SAP) was measured as described 
previously (Schermuly et al., 2005). Next the right jugular vein was isolated. A silicon 
catheter connected to a fluid filled transducer was inserted into the jugular vein through 
incision and right ventricular systolic pressure (RVSP) was measured. Before measuring 
RVSP, 0.5ml of heparin solution was administered through jugular vein. The computer 
software Labtech Notebook Runtime version 9.02 was used for recording the pressure for 
5-10 minutes 
 
For mice, the anesthesia dose combination was xylazin, ketamine and saline in the ratio of 
1:1:2 and the rest of the procedure was similar. Before anesthetizing the mice, heparin was 
injected to reduce the blood coagulation. 
 
2.2.6 Blood gas analysis / Hemoglobin concentration 
 
During the hemodynamic procedure in Zucker rats, arterial and venous blood were taken 
separately and a blood gas analysis was performed in Rapidlab
TM 
348 for measuring the 
blood gas components. For B6 mice, arterial blood was taken in the hematocrit tube and 
analyzed in the Rapidlab
TM




2.2.7 Body mass index 
 
Body mass index (BMI) was calculated in both mice and rats with the following formula: 
   BMI = weight in grams / length in centimeters
2 
  
The length of the body of both mice and rats were considered from the tip of the nose until 
the base of the tail (Fig. 9).  
 
 
Fig. 9: Depiction of the way by which the length of mice or rats was measured using a ruler. 
 
 
2.2.8 Tissue harvesting / paraffin embedding / storage of tissues and plasma 
 
At the end of hemodynamic procedure, animal was sacrificed. The chest cavity was 
opened. Lungs were flushed through pulmonary artery with 0.9% normal saline to make it 
free of blood. Right lung lobes were taken for molecular biology. For this it was taken out 
and frozen in liquid nitrogen and stored in -80
o
C. The left lung was taken for histological 
analysis. For this the lung was taken in 3.5% formaldehyde and kept in 4
o
C overnight. 
Then the tissue was changed to 1x PBS for 2 days. Finally, it was kept in embedding 
cassette in 70% alcohol for dehydration. The dehydration was done in automatic 




In order to analyze the right heart hypertrophy, the Fulton's index (RV/(LV+S)) was 
assessed. Briefly, the heart was excised to left ventricle + Septum (LV+S) and right 
ventricle (RV) and taken weight. Main part of both tissues were snap frozen in liquid 
nitrogen as for lung. Small part were kept in formalin for embedding. The process was 
similar to lungs. 
 
The blood collected was kept in the EDTA tubes and centrifuged in 10000 rpm for 10 






The tissue embedded in paraffin were sectioned into 3µm slices in microtome and stored in 
37
O
C in the incubator. 
 
Fig. 10: Histology procedures. A. Setup for invasive hemodynamic measurements in rats or 
mice. B. Dehydration machine for tissues. C. Paraffin embedding machine D. Paraffin embedded 






Fig. 11: Histology procedures. E. Microtome for cutting the paraffin embedded tissue samples 
into thin slices. F. Working place under the hood for staining of tissues. G. Antibody staining of 
the tissues. H. Light microscope and computer for analysis of the tissue sections.  
 
 
2.2.10 Medial wall thickness 
 
To assess the pulmonary vascular remodeling, the medial wall thickness analysis was 
performed, as we previously published and described (Dahal et al., 2011; Kosanovic et al., 
2011; Schermuly et al., 2005; Dahal et al., 2010). Medial wall thickness of pulmonary 
vessels is defined as the distance between the lamina elastic interna and externa. To 
measure the medial wall thickness van Gieson’s staining was used. The 3µm lung tissue 
sections were deparaffinised and rehydrated. After overnight staining in Resorcin-Fuchsin, 
the slides with the tissue sections were washed with water. The sections were immersed in 
Weigert’s working solution of hematoxylin for 5 minutes. The Weigert’s working is 
prepared by mixing equal volume of Weigert’s Iron Hematoxylin A and Weigert’s Iron 
Hematoxylin B (i.e. in the ratio of 1:1). The sections were washed with running water and 
then with aquadest. After washing, the slides were immersed in van Gieson solution for 10 





). Vessels with outer diameter of 20-50µm were used for 
analysis. Light microscope with Leica Qwin V3 computer-assisted image analysis software 
was used for analysis. Elastic fibers and cell nuclei are stained dark blue or dark brown by 
the iron-hematoxylin stain. Collagen and muscle fibers are stained red by the van Gieson 
counterstain. Cytoplasm is stained yellow due to counterstain 
 
2.2.11 Degree of Muscularization 
 
Another well-established method for assessment of the pulmonary vascular remodeling, the 
degree of muscularization was performed, as we previously published and described (Dahal 
et al., 2011; Kosanovic et al., 2011; Schermuly et al., 2005; Dahal et al., 2010). 
Muscularization of pulmonary vessels was analyzed by performing double immuno-
staining with anti-alpha smooth muscle actin (α SMA) antibody (Sigma Aldrich) and anti 
von-Willebrand factor (vWF) antibody (Dahal et al., 2010; Schermuly et al., 2005). 3µm 
lung tissue sections were deparaffinised and rehydrated. The endogenous peroxidase 
activity of the tissue was blocked by using freshly prepared solution of 30% hydrogen 
peroxide (H2O2) in methanol in 1:1 ratio. The sections were then washed with 1x PBS with 
pH 7.4. The composition of 20x PBS: NaCl: 80gm, KCl: 2gm, Na2HPO4x2H2O: 11.5gm, 
KH2PO4: 2gm and A-dest: 900ml and stored for longer use. This stock solution was used to 
prepare 1x PBS. Antigen retrieval was performed with trypsin at 37
o
C for 15 minutes and 
then washed with 1x PBS. To avoid the non-specific binding, the slides were first 
incubated with 10% BSA for 15 minutes and washed with PBS. Incubation with normal 
horse serum was done for 30 minutes to avoid the non-specific bindings caused by the 
immunoglobulin cross-reactivity. For staining of the pulmonary vascular smooth muscle, 
anti-alpha smooth muscle actin antibody was used in the dilution ratio of 1:900 in 10% 
BSA for 30 minute. Biotinylated secondary antibody was used for 30 minutes. VIP 
substrate was used to develop color by reaction with streptavidin peroxidase complex 
coupled to secondary antibody. Smooth muscle layer developed the purple/violet color. For 
staining the endothelium, the same slides were washed with 1x PBS, incubated with 10% 
BSA for 15 minutes and washed again. Incubation with 2.5 % normal horse serum 
(ImPRESS kit Anti-Rabbit Ig Peroxidase) was done for 30 minutes. The slides were 
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incubated with the primary antibody anti-von Willebrand factor in the dilution ratio of 
1:1200 in 10% BSA for 30 minutes at 37
o
C. After washing with 1x PBS, secondary 
antibody ImmPRESS reagent anti-rabbit peroxidase was added. Visualization of staining 
was done by DAB substrate which shows brown color of the vascular endothelium. The 
sections were counter stained with methyl green in the hot plate for 3 minutes and 
dehydrated, then cover-slipped with mounting medium. The sections were examined by 
light microscope using a computerized system (Qwin, Leica). Vessels with 20-50µm size 
were used for analysis. Each vessel was categorized as fully muscularized (70-100%), 
partially muscularized (5-70%) or non-muscularized (0-5%) 
 
For mice, the 3µm lung tissue sections were deparaffinised and rehydrated similar to rat 
tissue. The endogenous peroxidase activity of the tissue was blocked by using freshly 
prepared solution of 30% hydrogen peroxide (H2O2) in methanol in 1:10 ratio. Other steps 
were similar till BSA blocking. As mouse primary antibody should be used in the mice 
tissues, so Mouse- on- Mouse HRP polymer kit was used to reduce the cross reactivity. 
This kit consisted of Rodent block M and MM HRP polymer. The Rodent block M was 
used for 30 minutes.  For staining pulmonary vascular smooth muscle, anti-alpha smooth 
muscle actin antibody was used in the dilution ratio of 1:900 in 10% BSA for 30 minute. 
After washing with 1x PBS, the antigen antibody reaction was visualized by adding MM 
HRP polymer and then VIP substrate kit. Other steps were done similar as for rat tissues. 
 
2.2.12 CD68 staining 
 
To identify macrophages in the lung tissues, CD68 staining was performed, similarly as we 
published and described before (Savai et al., 2012). The 3µm section of lung tissue were 
deparaffinised and rehydrated. For antigen retrieval, the slides were cooked with citrate 
buffer 20x for 20 minutes. The citrate buffer solution was prepared with 95ml aquadest and 
5 ml 20x citrate buffer with pH 6. The endogenous peroxidase activity of the tissue was 
blocked by using freshly prepared solution of 30% hydrogen peroxide (H2O2) in methanol 
in 1:1 ratio. The slides were washed with aquadest and 1x PBS. The slides were again 
incubated in proteinase K at room temperature for 15 minutes. The slides were washed 
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with aquadest and PBS and incubated with 10% BSA. The slides were then washed with 1x 
PBS and incubated with 2.5 % normal horse serum (ImPRESS kit Anti-Mouse Ig 
Peroxidase) for 30 minutes. The slides were incubated with the primary antibody anti-Rat 
CD68 (MCA341R, AbD Serotec) in the dilution ratio of 1:100 in 10% BSA overnight at 
4
o
C. After washing with 1x PBS, secondary antibody ImmPRESS reagent anti-mouse 
peroxidase was added. Visualization of staining was done by NovaRED substrate. Counter 
staining was done with hematoxylin and dehydration steps were performed. The procedure 
was completed by covering the slide with mounting medium and putting the coverslip. The 
CD68 positive cells would appear brown in the light microscope and counted manually.  
 
2.2.13 Statistical analysis 
 
Values are expressed as Mean ± SEM (Standard error of mean). The different experimental 
groups were compared by one way ANOVA (Analysis of variance). The Newman Keuls 





3.1 Body mass index of male Zucker rats 
 
The body mass index was measured before the final hemodynamic measurements on day 
35. The obese rats acquired significantly higher body mass index than their lean 
counterparts. However, there was a noticeably decreased value of the body mass index in 
both lean and obese groups of monocrotaline injected Zucker rats. 
 
 
Fig. 12: Body mass index of lean and obese male Zucker rats was assessed after 5 weeks of either 
NS or MCT treatment. NS = normal saline, MCT = monocrotaline, BMI = body mass index. Data 
are mean ± SEM, p value ≤ 0.05 are significant, n = 8-11, *compared to lean, $compared to normal 
saline 
  
3.2 Echocardiographic parameters of MCT induced PH in male Zucker rats 
 
Echocardiography was done at two time points - 3 weeks and 5 weeks after normal saline 
or monocrotaline (MCT) injection to lean or obese male Zucker rats. In general, 5 weeks 
upon MCT injection both lean and obese Zucker rats developed PH, as evident by 
increased value of RVID and RVWT, and noticeably reduced values of TAPSE, 
PAAT/PAET and CI. On the other hand, minor differences were noticed between groups in 
echocardiography parameters such as RVID, RVWT, TAPSE and CI done in 3 weeks (Fig. 
13-A, B, C and E). Interestingly, PAAT/PAET showed a remarkable difference in the MCT 
obese group between 3 and 5 weeks (Fig. 13-D).  
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Fig. 13: Echocardiographic parameters of lean and obese male Zucker rats were assessed after 3 and 
5 weeks of either NS or MCT treatment. A. to E. Right ventricular internal diameter, right 
ventricular free wall thickness, tricuspid annular plane systolic excursion, ratio of pulmonary artery 
acceleration time to ejection time and cardiac index respectively, measured at 3 and 5 weeks. NS = 
normal saline, MCT = monocrotaline, RVID = right ventricular internal diameter, RVWT = right 
ventricular free wall thickness, TAPSE = tricuspid annular plane systolic excursion, PAAT = 
pulmonary artery acceleration time, PAET = pulmonary artery ejection time, CI = cardiac index. 






3.3 Hemodynamic and right heart hypertrophy features of MCT induced PH in 
male Zucker rats 
 
Invasive hemodynamic and right ventricular hypertrophy parameters were assessed at 5 
weeks of normal saline or monocrotaline injection. Minor differences were seen for the 
systemic arterial pressure. A significant increase in the RVSP as well as Fulton's index 
showed a prominent manifestation of PH in the MCT lean and obese groups of Zucker rats 
(Fig. 14-A and B), compared to their respective saline controls. No change between the 
MCT injected lean and obese groups was observed.     
             
                 A. 
 
 
                                             B. 
 
Fig. 14: Hemodynamic measurements and Fulton's index of lean and obese male Zucker rats were 
assessed after 5 weeks of either NS or MCT treatment. A. Systemic arterial pressure and right 
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ventricle systolic pressure measured invasively at 5 weeks after normal saline or monocrotaline 
injection. B. Ratio of right ventricle to left ventricle + septum measured at 5 weeks of normal saline 
or monocrotaline injection. NS = normal saline, MCT = monocrotaline, SAP = systemic arterial 
pressure, RV = right ventricle, LV = left ventricle, S = septum. Data are mean ± SEM, p value ≤ 
0.05 are significant, n = 2-11, 
*
compared to lean, 
$
compared to normal saline 
 
3.4 Survival rate in obese male Zucker rats 
 
The overall mortality was higher for the obese male Zucker rats than their lean counterparts 
treated with MCT (Fig. 15). No mortality was seen in both the groups until 4 weeks. The 
mortality started later in the obese groups but with higher degree of severity.   
 
Fig. 15: Survival rate of lean and obese male Zucker rats. Survival percentage was evaluated until 5 
weeks of either NS or MCT treatment. NS = normal saline, MCT = monocrotaline. Data are mean ± 
SEM, p value ≤ 0.05 are significant, n = 10-15, *compared to lean, $compared to normal saline 
 
3.5 Pulmonary vascular remodeling effects of MCT in male Zucker rats 
 
Pulmonary vascular remodeling in the distant pulmonary vessels was assessed via 
measuring the medial wall thickness and the degree of muscularization. In agreement with 
hemodynamic and non-invasive data, a substantial enhancement in medial wall thickness 
and fully muscularized vessels were found out in the MCT injected Zucker rats, compared 
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to their saline controls. However, no differences between the lean and obese groups were 
seen. On the other hand, the number of non-muscularized vessels was lower in both lean 
and obese MCT injected groups, in comparison to their respective saline controls (Fig. 16-
B). Therefore, in agreement with hemodynamic, right heart hypertrophy and non-invasive 
echocardiographic parameters, pulmonary vascular remodeling also revealed that there was 
no difference in the PH severity between lean and obese rats.   
 
 
                A 
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Fig. 16: Medial wall thickness and degree of muscularization in lean and obese male Zucker rats 
were assessed after 5 weeks of either NS or MCT treatment. Lung tissues were sliced at 3 µm 
sections for staining. van Gieson's staining was done to measure the medial wall thickness. The 
distance between lamina elastic interna and externa was measured. Double immuno-staining with 
anti-alpha smooth muscle actin (α SMA) antibody and anti-von-Willebrand factor (vWF) antibody 
was done to measure the degree of muscularization. A and B. Medial wall thickness and degree of 
muscularization for lean and obese male Zucker rats treated either with normal saline or 
monocrotaline solution. C. Representative images for medial wall thickness (arrows indicate the 
pulmonary vessel).  NS = normal saline, MCT = monocrotaline. Data are mean ± SEM, p value ≤ 
0.05 are significant, n = 6-11, 
*
compared to lean, 
$
compared to normal saline. 
 
3.6 Inflammatory effect of MCT in obese male Zucker rats 
 
The inflammatory effects of MCT were traced via the presence of CD68 (Cluster of 
Differentiation 68) positive macrophages. CD68 staining was done on the paraffin 
embedded lung tissues. High infiltration of CD68 positive cells were detected in both lean 
and obese MCT groups, compared to their respective saline controls. However, a 
significantly higher infiltration in the obese MCT group compared to the lean MCT group 
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Fig. 17: CD68 (macrophages) positive cells counting in the lung tissues of lean and obese male 
Zucker rats was assessed after 5 weeks of either NS or MCT treatment. Lung tissues were sliced at 3 
µm sections for staining. Staining with anti-CD68 antibody was done.  A. Quantification of CD68 
positive cells from paraffin embedded lung tissues from lean and obese male Zucker rats treated with 
either normal saline or monocrotaline. B. Representative images for CD68 staining in Zucker rats 
lung tissues (arrows indicate the CD68 positive cells).  NS = normal saline, MCT = monocrotaline. 
Data are mean ± SEM, p value ≤ 0.05 are significant, n = 6-11, *compared to lean, $compared to 
normal saline.  
 
3.7 Body mass index in obese female Zucker rats 
 
The body mass index was measured before the final hemodynamic measurements on day 
35. The obese female rats acquired significantly higher body mass index than their lean 
counterparts. Unlike in the case of male Zucker rats, MCT injection per se did not change 





Fig. 18: Body mass index of lean and obese female Zucker rats was assessed after 5 weeks of either 
NS or MCT treatment. NS = normal saline, MCT = monocrotaline, BMI = body mass index. Data 
are mean ± SEM, p value ≤ 0.05 are significant, n = 10, *compared to lean, $compared to normal 
saline 
 
3.8 Echocardiographic parameters of MCT induced PH in female rats 
 
For female Zucker rats, echocardiography was also done at two instances - 3 weeks and 5 
weeks after normal saline or MCT injection to lean or obese female Zucker rats. Increase in 
RVID and RVWT was evident from the third week of MCT injection and it was more 
prominent in the fifth week, compared to the saline controls. Importantly, both of the 
parameters, were more severe in the obese female Zucker rats (Fig. 19-A and B), compared 
to their lean controls. In agreement, PAAT/PAET was reduced after 5 weeks in MCT 
female Zucker rats in comparison to their saline controls, and even further decreased in 
obese versus lean MCT rats. Similarly, TAPSE was prominently reduced in obese MCT 
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Fig. 19: Echocardiographic parameters of lean and obese female Zucker rats were assessed after 3 
and 5 weeks of either NS or MCT treatment. A. to E. Right ventricular internal diameter, right 
ventricular free wall thickness, tricuspid annular plane systolic excursion, ratio of pulmonary artery 
acceleration time to ejection time, cardiac output and cardiac index respectively, measured at 3 and 5 
weeks. NS = normal saline, MCT = monocrotaline, RVID = right ventricular internal diameter, 
RVWT = right ventricular free wall thickness, TAPSE = tricuspid annular plane systolic excursion, 
PAAT = pulmonary artery acceleration time, PAET = pulmonary artery ejection time, CI = cardiac 
index. Data are mean ± SEM, p value ≤ 0.05 are significant, n = 10, *compared to lean, $compared to 
normal saline 
 
3.9 Hemodynamic features of MCT induced PH in female Zucker rats 
 
Invasive hemodynamic and right heart hypertrophy parameters were assessed at 5 weeks of 
normal saline or monocrotaline injection. No differences were seen for the systemic arterial 
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pressure. In agreement with non-invasive echocardiography data, a significant increase in 
the RVSP and Fulton's index was observed in MCT injected obese female Zucker rats, 
compared to their saline controls and lean counterparts. The lean female Zucker rats 
remained not significantly affected by the MCT injection in the terms of RVSP and 
Fulton's index (Fig. 20-A and B).  
                A 
 
                                             B                        
 
Fig. 20: Hemodynamic measurements and Fulton's index of lean and obese female Zucker rats were 
assessed after 5 weeks of either NS or MCT treatment. A. Systemic arterial pressure and right 
ventricle systolic pressure measured invasively at 5 weeks after normal saline or monocrotaline 
injection. B. Ratio of right ventricle to left ventricle + septum measured at 5 weeks of normal saline 
or monocrotaline injection. NS = normal saline, MCT = monocrotaline, SAP = systemic arterial 
pressure, RV = right ventricle, LV = left ventricle, S = septum. Data are mean ± SEM, p value ≤ 
0.05 are significant, n = 10, 
*
compared to lean, 
$




3.10 Survival curve of MCT induced PH in female Zucker rats 
 
No mortality was seen in female Zucker rats injected with MCT (Fig. 21). 
 
Fig. 21: Survival rate of lean and obese female Zucker rats. Survival percentage was evaluated until 
5 weeks of either NS or MCT treatment. NS = normal saline, MCT = monocrotaline. Data are mean 
± SEM, p value ≤ 0.05 are significant, n = 10, *compared to lean, $compared to normal saline 
 
3.11 Pulmonary vascular remodeling effects due to MCT in female Zucker rats 
 
Pulmonary vascular remodeling in the distant pulmonary vessels was assessed in female 
Zucker rats in an identical manner as that of the male Zucker rats. Interestingly, the medial 
wall thickness was increased in MCT injected lean and obese female Zucker rats compared 
to their respective saline controls, as well as in normal saline treated obese female group in 
comparison to its lean counterpart. Importantly and in agreement with physiological in vivo 
data, there was a prominent augmentation of medial wall thickness in the MCT treated 
obese females, compared to their MCT lean counterparts. Similar results were seen for the 
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Fig. 22: Medial wall thickness and degree of muscularization of lean and obese female Zucker rats 
were assessed after 5 weeks of either NS or MCT treatment. Lung tissues were sliced at 3 µm 
sections for staining. van Gieson's staining was done to measure the medial wall thickness. The 
distance between lamina elastic interna and externa was measured. Double immuno-staining with 
anti-alpha smooth muscle actin (α SMA) antibody and anti-von-Willebrand factor (vWF) antibody 
was done to measure the degree of muscularization. A and B. Medial wall thickness and degree of 
muscularization for lean and obese female Zucker rats treated either with normal saline or 
monocrotaline solution. C. Representative images for medial wall thickness (arrows indicate the 
pulmonary vessel).  NS = normal saline, MCT = monocrotaline. Data are mean ± SEM, p value ≤ 
0.05 are significant, n = 10, 
*
compared to lean, 
$




3.12 Inflammatory effect of MCT in female Zucker rats 
 
The inflammatory effects of MCT were traced in identical way as that of male Zucker rats. 
Higher infiltration of CD68 positive cells were detected in both lean and obese MCT 
groups compared to their saline injected controls. Furthermore, it was obvious that obesity 
induced a noticeably increased CD68 positive cell counts in both saline and MCT treated 
female Zucker rats, in comparison to their lean counterparts (Fig. 23-A).  
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Fig. 23: CD68 (macrophages) positive cells counting in the lung tissues of lean and obese female 
Zucker rats was assessed after 5 weeks of either NS or MCT treatment. Lung tissues were sliced at 3 
µm sections for staining. Staining with anti-CD68 antibody was done. A. Quantification of CD68 
positive cells from paraffin embedded lung tissues from lean and obese female Zucker rats treated 
with either normal saline or monocrotaline. B. Representative images for CD68 staining in female 
Zucker rats lung tissues (arrows indicate CD68 positive cells).  NS = normal saline, MCT = 
monocrotaline. Data are mean ± SEM, p value ≤ 0.05 are significant, n = 8-10, *compared to lean, 
$




3.13 Body mass index of lean and obese B6 male mice 
 
The body mass index was measured similar to the Zucker rats, before the final 
hemodynamic measurements on day 35. The obese mice acquired significantly higher body 
mass index than their lean counterparts. However, there was a slight decrease of body mass 
index in obese male mice under hypoxia exposure, compared to their normoxic control 
(Fig. 24) 
 
Fig. 24: Body mass index of lean and obese male B6 mice was assessed after 5 weeks of either 
normoxic or hypoxic (10% Oxygen level) conditions. WT = wild type, OB = obese, NOX = 
normoxia, HOX = hypoxia, BMI = body mass index. Data are mean ± SEM, p value ≤ 0.05 are 
significant, n = 10-20, 
*
compared to wild type 
 
 
3.14 Echocardiographic parameters of hypoxia induced PH in B6 male mice 
 
Echocardiography in male B6 mice was done similar to Zucker rats, at two time points - 3 
weeks and 5 weeks after normoxic or hypoxic conditions. Increase in RVID and RVWT 
was apparent in both lean and obese mice exposed to hypoxia, compared to their normoxic 
controls. However, the RVID was reduced in obese mice compared to the lean under the 
hypoxic condition. Surprisingly, RVWT was altered in essentially opposite manner, it was 
increased in obese versus lean mice under hypoxia. TAPSE and PAAT/PAET were 
decreased in both hypoxic groups compared to their normoxic controls. However, there 
was a slight increase in both parameters in obese mice in comparison to their lean 
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counterparts under the hypoxic condition. Finally, CI was decreased in obese animals 
compared to the lean groups under both normoxic and hypoxic conditions.  
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Fig. 25: Echocardiographic parameters of lean and obese male B6 mice were assessed after 3 and 5 
weeks of either normoxic or hypoxic (10% Oxygen level) conditions. A. to E. Right ventricular 
internal diameter, right ventricular free wall thickness, tricuspid annular plane systolic excursion, 
ratio of pulmonary artery acceleration time to ejection time, cardiac output and cardiac index 
respectively, measured at 3 and 5 weeks. WT = wild type, OB = obese, NOX = normoxia, HOX = 
hypoxia, RVID = right ventricular internal diameter, RVWT = right ventricular free wall thickness, 
TAPSE = tricuspid annular plane systolic excursion, PAAT = pulmonary artery acceleration time, 
PAET = pulmonary artery ejection time, CI = cardiac index. Data are mean ± SEM, p value ≤ 0.05 
are significant, n = 9-20, *compared to wild type, 
$






3.15 Hemodynamic features of hypoxia induced PH in B6 male mice 
 
Invasive hemodynamic parameters were assessed at 5 weeks of normoxia or hypoxia 
treatments in lean or obese B6 mice. No differences were seen in any groups for the 
systemic arterial pressure. A lower RVSP for both normoxic and hypoxic obese mice 
compared to their respective lean controls and higher RVSP due to hypoxia was observed. 
Nevertheless, hypoxia rendered significantly higher Fulton's index, but no effects of 
obesity was seen.  
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Fig. 26: Hemodynamic measurements and Fulton's index of lean and obese male B6 mice were 
assessed after 5 weeks of either normoxic or hypoxic (10% Oxygen level) conditions. A. Systemic 
arterial pressure and right ventricle systolic pressure measured invasively at 5 weeks after normoxic 
or hypoxic conditions. B. Ratio of right ventricle to left ventricle + septum measured at 5 weeks of 
normoxic or hypoxic conditions. WT = wild type, OB = obese, NOX = normoxia, HOX = hypoxia, 
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SAP = systemic arterial pressure, RV = right ventricle, LV = left ventricle, S = septum. Data are 




3.16 Pulmonary vascular remodeling in hypoxia induced PH in B6 male mice 
 
Pulmonary vascular remodeling in the distant pulmonary vessels was assessed similar to 
those of Zucker rats. Medial wall thickness and the degree of muscularization were 
calculated. Increase in medial wall thickness and fully muscularized vessels were found in 
the groups exposed to hypoxia compared to the normoxic conditions, except for obese mice 
with regard to the medial wall thickness where the difference was not that prominent. 
Surprisingly, there was a reduction in medial wall thickness and fully muscularized vessels 
in obese versus lean mice under hypoxic condition. 
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Fig. 27: Medial wall thickness and degree of muscularization of lean and obese male B6 mice were 
assessed after 5 weeks of either normoxic or hypoxic (10% oxygen level) conditions. Lung tissues 
were sliced at 3 µm sections for staining. van Gieson's staining was done to measure the medial wall 
thickness. The distance between lamina elastic interna and externa was measured. Double immuno-
staining with anti-alpha smooth muscle actin (α SMA) antibody and anti-von-Willebrand factor 
(vWF) antibody was done to measure the degree of muscularization. A and B. Medial wall thickness 
and degree of muscularization for lean and obese female Zucker rats treated either with normoxic or 
hypoxic conditions. WT = wild type, OB = obese, NOX = normoxia, HOX = hypoxia. Data are 
mean ± SEM, p value ≤ 0.05 are significant, n = 5, *compared to wild type, $compared to normoxia  
 
3.17 Body mass index in lean and obese B6 female mice 
 
The body mass index was measured similar to the male B6 mice. The obese female mice 
acquired significant higher body mass index than their lean counterparts. A slight effect of 
hypoxia in terms of decreased body mass index in obese female mice was seen (Fig. 28) 
 
 
Fig. 28: Body mass index of lean and obese female B6 mice was assessed after 5 weeks of either 
normoxic or hypoxic (10% Oxygen level) conditions. WT = wild type, OB = obese, NOX = 
normoxia, HOX = hypoxia, BMI = body mass index. Data are mean ± SEM, p value ≤ 0.05 are 
significant, n = 10, 
*
compared to wild type, 
$







3.18 Echocardiographic parameters of hypoxia induced PH in B6 female mice 
 
Echocardiography in female B6 mice was done identical to the male B6 mice. Increase in 
RVID and RVWT were apparent after 3 and 5 weeks of hypoxia in both lean and obese 
mice, compared to the normoxic controls. Interestingly, there was a further increase in both 
parameters particularly in obese hypoxic mice in comparison to their lean counterparts. 
Other parameters such as TAPSE and PAAT/PAET were decreased in both lean and obese 
mice under hypoxic condition, compared to the respective normoxic controls. A slight 
alteration in TAPSE was also seen in obese mice versus lean under hypoxic condition. CI 
was decreased in obese group as compared to the lean counterparts. These effects were 
constant during the 5 week measurements.  
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Fig. 29: Echocardiographic parameters of lean and obese female B6 mice were assessed after 3 and 
5 weeks of either normoxic or hypoxic (10% Oxygen level) conditions. A. to E. Right ventricular 
internal diameter, right ventricular free wall thickness, tricuspid annular plane systolic excursion, 
ratio of pulmonary artery acceleration time to ejection time, cardiac output and cardiac index 
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respectively, measured at 3 and 5 weeks. WT = wild type, OB = obese, NOX = normoxia, HOX = 
hypoxia, RVID = right ventricular internal diameter, RVWT = right ventricular free wall thickness, 
TAPSE = tricuspid annular plane systolic excursion, PAAT = pulmonary artery acceleration time, 
PAET = pulmonary artery ejection time, CI = cardiac index. Data are mean ± SEM, p value ≤ 0.05 
are significant, n = 8-10, *compared to wild type, 
$
compared to normoxia 
 
3.19 Hemodynamic features of hypoxia induced PH in B6 female mice 
 
Invasive hemodynamic parameters were assessed similar to male B6 mice. No differences 
were seen in any groups for the systemic arterial pressure. Hypoxic female mice developed 
higher RVSP and Fulton's index, compared to the normoxic controls. No prominent effect 
of obesity was observed under hypoxia, except slight increase of RVSP in obese female 
mice, compared to the lean control.  
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Fig. 30: Hemodynamic measurements and Fulton's index of lean and obese female B6 mice were 
assessed after 5 weeks of either normoxic or hypoxic (10% Oxygen level) conditions. A. Systemic 
arterial pressure and right ventricle systolic pressure measured invasively at 5 weeks after normoxic 
or hypoxic conditions. B. Ratio of right ventricle to left ventricle + septum measured at 5 weeks of 
normoxic or hypoxic conditions. WT = wild type, OB = obese, NOX = normoxia, HOX = hypoxia, 
SAP = systemic arterial pressure, RV = right ventricle, LV = left ventricle, S = septum. Data are 
mean ± SEM, p value ≤ 0.05 are significant, n = 8-10, *compared to wild type, $compared to 
normoxia. 
 
3.20 Pulmonary vascular remodeling in hypoxia induced PH in B6 female mice 
 
Pulmonary vascular remodeling in the distant pulmonary vessels were assessed similar to 
those male B6 mice. Wild type mice developed increased medial wall thickness due to 
hypoxia but obese mice did not show this increment. Higher degree of fully muscularized 
vessels were present in both hypoxic wild type and obese mice (Fig. 31-A and B). 
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Fig. 31: Medial wall thickness and degree of muscularization of lean and obese female B6 mice 
were assessed after 5 weeks of either normoxic or hypoxic (10% oxygen level) conditions. Lung 
tissues were sliced at 3 µm sections for staining. van Gieson's staining was done to measure the 
medial wall thickness. The distance between lamina elastic interna and externa was measured. 
Double immuno-staining with anti-alpha smooth muscle actin (α SMA) antibody and anti-von-
Willebrand factor (vWF) antibody was done to measure the degree of muscularization. A and B. 
Medial wall thickness and degree of muscularization for lean and obese female B6 mice treated 
either with normoxic or hypoxic conditions. WT = wild type, OB = obese, NOX = normoxia, HOX = 
hypoxia. Data are mean ± SEM, p value ≤ 0.05 are significant, n = 5, *compared to wild type, 
$






In general, the results from the study revealed the following findings: 
 
1) Obesity in male Zucker rats did not influence the disease severity in MCT-induced 
PH. However, there was a clear increase in lung inflammation due to obesity, in 
comparison to lean controls. 
 
2) Furthermore, the data demonstrated that obesity significantly aggravated the MCT-
induced PH in female Zucker rats, compared to their lean controls. These findings 
indicated potentially different influence of obesity with regard to the gender in the 
context of inflammatory model of PH, such as MCT. 
 
3) Finally, obesity exhibited negligible effects in hypoxia-induced PH in male and 
female obese mice, compared to their respective lean controls.  
 
This research was aimed to find the potential relation between obesity and pulmonary 
hypertension. Along with an obese factor, a clear presentation of male and female 
characteristics was aimed in the context of PH. To exert an extended explanation for the 
complex entity of PH, two different models were utilized - MCT and hypoxia model of PH 
in rats and mice respectively. Both of this models have been successfully and efficaciously 
used to characterize PH in rats and mice with excellent reproducible results (Dumitrascu et 
al., 2008; Stenmark et. al., 2006; Schermuly et al., 2004). 
 
MCT, a macrocyclic pyrrolizidine alkaloid, after its application, converts into its active and 
toxic form, causing inflammatory response and pulmonary injury and non-reversible 
epithelial damage. Pyrrolizidine alkaloid toxicity, mainly hepatic necrosis, and deaths have 
also been reported in humans and animals after accidental ingestion of Crotalaria or other 
related plants (Wilson et al., 1992). Hypoxia, on the other hand, causes different but 
distinctive form of pulmonary vessels remodeling which presents the differentiation of 
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immature smooth muscle cells leading to increased migration, proliferation or matrix 
protein production (Stenmark et al., 2006).  
 
The role of obesity in PH is still unclear, neither suggesting as a friend nor as a foe against 
this condition. Studies particularly accessing the association between obesity and 
pulmonary hypertension have shown no relation with class I obesity, but a higher 
probability of connection with class II or III obesity (Williams III et al., 2010). A typical 
study done on a moderately high altitude illustrated a higher prevalence of diurnal PH in 
obese patients. Obesity hypoventilation syndrome was predicted as the main risk factor 
(Valencia-Flores et al., 2004).  
 
Diet induced obesity in rats have shown to develop various features such as pulmonary 
artery remodeling, elevated pulmonary artery pressure and right ventricular hypertrophy. 
The obese rats featured hyperlipidemia, oxidant damage and high circulating inflammatory 
cytokines but did not show any evidence of hypoventilation or chronic hypoxia-like 
features (Irwin et al., 2014). High fat diet fed obese mice demonstrated an upregulation of 
the genes of cardiac endothelin system. The plasma levels of endothelin-1 as well as 
endothelin receptors A and B protein expression were also higher in those mice (Catar et. 
al., 2014) suggesting a predisposition for PH or pulmonary disease. Increased inflammation 
and oxidative stress are associated independently with obesity or PH and administration of 
antioxidant supplementation in either case is shown to be beneficial (Bowers et al., 2004; 
Musaad and Haynes 2007). Obesity with the association of inflammatory markers and 
oxidative stress might be an essential factor for PH development.  
 
The gender in humans also affect the prevalence or survival due to PH. Earlier believed to 
be more frequent in younger females, PAH has gradually lurched to nullify this gender 
dominance. Equally balanced gender patients at older age but with higher severity and 
lower therapy response was observed by European based medial therapies for PH - 
COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for 
Pulmonary Hypertension) (Hoeper, et al., 2013). A radically distinctive study has shown a 
greater percentage of females within the patients who were obese but not diabetic (Poms et 
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al., 2013). Intriguingly, females show better survival probabilities than the males. 
Interestingly, animal studies have shown for estrogens to have protective role in animal 
models of PH (Lahm et al., 2014).    
 
Having these confounding results both with regard to obesity and gender versus PH, it 
gives a great opportunity to unravel these research questions. In general, the results of 
MCT-induced PH in Zucker male rats revealed that the obesity did not influence 
significantly the disease severity. However, more prominent inflammation was still present 
in the lungs of obese versus lean male rats upon MCT injections. Female Zucker rats, on 
the other hand, showed less effects of MCT-induced PH, but a higher severity of the 
disease in the obese females than those of leans. Both obesity and gender appeared to alter 
the normal and established norms and understanding on the topic. Therefore, obesity may 
represent an important factor which modulates the PH development in the context of 
females. In the case of hypoxia-induced PH, obesity was not shown to play an important 
role neither in male nor female gender.  
 
4.1 MCT-induced PH in lean and obese male Zucker rats 
 
For inducing obesity in male rats, leptin receptor recessive Zucker rats (Crl:ZUC-Lepr
fa
) 
were used from Charles River Laboratories together with their lean counterpart. For PH 
development in rats, widely used MCT model at a dose of 60 mg MCT per kg body weight 
was followed. It has been successfully utilized in several experiments showing prominent 
features of PH in various rat species (Gomez-Arroyo et al., 2012; Kosanovic et al., 2011; 
Schermuly et al., 2004). The difference of final body mass index for lean and obese groups 
were significant for the evaluation of the results. In order to track down the potential 
magnitude of disease progression, assessment of the echocardiography data were done at 
two instances - 3 weeks and 5 weeks.  
 
Both the lean and obese groups of Zucker rats injected with MCT presented severe form of 
PH as revealed by increase in RVID and RVWT as well as decrease in TAPSE, 
PAAT/PAET and CI (Fig. 13-A to E). The severity of PH was confirmed by elevation of 
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right ventricular systolic pressure and Fulton's index (Fig. 14-A and B) and with the 
assessment of the pulmonary vascular remodeling of distal pulmonary vessels (Fig. 16-A 
and B).  
 
However, the difference between the end stage severity of lean and obese male Zucker rats 
in terms of echocardiographic parameters, hemodynamic measurements and pulmonary 
vascular remodeling was not evident. In addition, there was little or non-significant 
fluctuations of 3 weeks echocardiographic parameters except PAAT to PAET ratio, in 
which obese male Zucker rats had significantly better performance (Fig. 13-D). CI in obese 
male rats was also slightly better, albeit not significant (Fig. 13-E).   
  
The survival percentage in MCT injected lean and obese male Zucker rats were recorded. 
After the MCT injection, the rats were observed in daily basis and duly assigned a score for 
its body condition to access the distress in the body. The mortality in MCT injected lean 
male Zucker rats started at day 28, couple of days earlier than MCT injected obese male 
Zucker rats. However, the end stage mortality (day 35) in obese ones was higher than those 
of leans (73.3% survival rate of lean rats versus 46.7% survival rate of obese) (Fig. 15). 
With similar end stage severity of PH parameters in both the groups, but higher mortality in 
obese male Zucker rats, it reserves a more profound study in the future to reveal if this 
observation is important.  
 
4.2 Higher inflammation in lung tissues of obese male Zucker rats 
 
To gain the insightful perspective for stimulation of immune system and degree of 
inflammation, macrophage specific CD68 positive cells were measured in the paraffin 
embedded lung tissues. Significant increase in the CD68 positive cells were seen. 
Infiltration of perivascular inflammatory cells in idiopathic PAH patients and MCT model 
have been characterized (Savai et al., 2012). Increased macrophages have been seen in the 
bronchoalveolar lavage fluid in the murine model (Tilton et al., 2013). Interestingly, obese 
male Zucker rats revealed significantly higher CD68 positive cells suggesting higher 
degree of inflammation or activation of the immune system, compared to their lean 
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counterparts (Fig. 17-A). This provides a clue of heightened inflammatory effects which 
might play crucial role for exasperation of disease severity in obesity in its chronic form.  
 
4.3 Milder PH features in female Zucker rats 
 
For inducing obesity in female rats, I used the females of the same variant of male Zucker 
rats. These leptin receptor recessive female Zucker rats (Crl:ZUC-Lepr
fa
), together with the 
lean counterpart, were also ordered from Charles River Laboratories. For PH development 
in female rats, the same MCT-model at a dose of 60 mg per kg body weight was 
implemented, similar to that of males. The difference of final body mass index for lean and 
obese groups was significant and echocardiography data were assessed at two instances - 3 
weeks and 5 weeks. The lean female Zucker rats were characterized by milder disease 
severity due to MCT administration compared to the males, as seen in the RVID, RVWT 
and PAAT/PAET. Furthermore, relatively less effects of MCT in the terms of Fulton's 
index or RVSP were also noted in the lean female groups. Pulmonary vascular remodeling 
(as assessed by increase in medial wall thickness and muscularization) was demonstrated, 
however, in less extent. This data corresponds with previous studies where researches were 
not able to show MCT effects in female Wistar rats (Lookin et. al., 2015).  
 
Female hormones have been attributed for this difference of MCT induced PH in male and 
female rats (Bal et al., 2013; Lookin et al., 2015). The group of Won-Jung Lee were able to 
show development of PH when both the ovaries from Sprague-Dawley rats were removed 
highlighting the importance of female hormones in PH progression (Ahn et al., 2003).  
 
4.4 Higher severity of disease in obese female Zucker rats 
 
Effects of MCT in obese female rats have not been documented earlier. This study provides 
important data about obese female Zucker rats which shows they are more prone to heart 
function damage and vascular remodeling following MCT injection. Consistent results of 
increased severity were found in terms of echocardiographic parameters, hemodynamic 
measurement, distal pulmonary vascular remodeling and CD68 positive macrophages. 
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Compared to their lean counterparts, 5 weeks post MCT data shows obese female Zucker 
rats had significantly higher RVID, RVWT as well as lower TAPSE and PAAT/PAET. A 
significant increase in Fulton's index and RVSP was also clearly observable in the obese 
female Zucker rats after the MCT injection. Likewise, medial wall thickening and 
muscularization of distal pulmonary arteries were also increased in the obese MCT female 
groups than those of the lean counterparts.  
 
The striking characteristics of MCT-induced PH in male Zucker rats were still not found in 
the female Zucker rats. The overall severity as compared to the male Zucker rats was less 
in females. The mean RVSP of female obese Zucker rats after 5 weeks of receiving MCT 
was 57.5 mmHg while this value for male obese Zucker rats after 5 weeks of receiving 
MCT was 71.33 mmHg. The Fulton's index of males were 0.43 versus 0.32 of females. 
There were no mortality due to MCT injection in the female group of rats while the 
mortality following MCT injection in males were 53%. This overall results implicated a 
milder form of disease in the obese females compared to that of obese males, but obesity is 
shown to modulate the PH development in the context of females and not in the males.  
  
4.5 Increased inflammation in obese female Zucker rats 
 
Macrophage specific CD68 positive cells were counted in the paraffin embedded lung 
tissues of female Zucker rats treated for 5 weeks with either normal saline or MCT. The 
procedures were similar to those adopted for male Zucker rats. An increase in the CD68 
positive cells were seen in all the female groups as compared to the lean females. This 
indicated increased inflammation and stimulation of immune system in obese females as 
well as MCT treated lean and obese females. A clearly alike augmentation of CD68 
positive cells infiltration was seen in the obese females treated with MCT as that of obese 
male Zucker rats. Therefore, it seems that inflammation may be one of the potential links 






Fig. 32: Scheme for the characterization of MCT induced PH in lean and obese Zucker rats of both 
of the genders. MCT = monocrotaline, TAPSE = tricuspid annular plane systolic excursion, PAAT = 
pulmonary artery acceleration time, PAET = pulmonary artery ejection time, RVSP = right 
ventricular systolic pressure. 
 
 
4.6 Hypoxia induced PH in lean and obese male mice 
 
Lean and obese male B6 mice were exposed to hypoxia (10% oxygen) for 5 weeks. PH due 
to hypoxia is officially listed in Group 3 in the updated clinical classification of PH 
(Simonneau et al., 2013). Hypoxia exposure to mouse has been robustly used as a model of 
PH in several studies (Dahal et al., 2012; Pak et al., 2010; Sommer et al., 2008). The body 
mass index in obese male mice was significantly higher than in their lean counterparts (Fig. 
24). 5 weeks long hypoxia exposure did not alter the BMI of lean or obese groups of mice. 
To access the development of PH, echocardiographic measurements were done at 3 and 5 




Evaluation of echocardiographic results at 3 weeks of hypoxic exposure showed clear 
manifestation of PH features with increase in RVID and RVWT and decrease in 
PAAT/PAET and TAPSE. Hypoxia has been known to develop clear PH features after 3 
weeks (Xia et al., 2014; Zhao et al., 2001). Increase in RVSP has been shown as early as 1 
week of hypoxia exposure (Xia et al., 2014). Echocardiographic features stayed mostly 
similar at 5 weeks of hypoxia exposure as that of 3 weeks for both the lean and obese mice. 
Hemodynamic measurements were done after 5 weeks of normoxia or hypoxia treatment. 
SAP were similar in all groups negating the changes of systemic hypertension. Both lean 
and obese mice showed elevated RVSP than the normoxic mice, however, the obese mice, 
both in normoxic or hypoxic conditions, presented lower RVSP than their lean 
counterparts. Fulton's index were higher for both groups of hypoxic mice, but no 
differences were seen between lean and obese mice.  
 
Remodeling of distal pulmonary arteries were evaluated in the same manner as Zucker rats. 
Increased medial wall thickness and muscularization was visible in both lean and obese 
hypoxic mice, compared to the normoxic groups.  
   
4.7 Hypoxia induced PH in lean and obese male mice 
 
Although some echocardiographic data (such as RVID, TAPSE and PAAT/PAET) and 
pulmonary vascular remodeling results show some mild "improvements" in obese versus 
lean male mice under hypoxia, other important measures, such as RVWT, RVSP and 
Fulton's index, do not reveal clear effects of obesity on hypoxia-induced PH. Therefore, 
our data do not convincingly support the significant influence of obesity in the context of 
chronic hypoxia exposure. In the line with these findings, it was demonstrated that mild 
form of PH is higher in obese patients who live at higher altitude with low oxygen level in 
the environment (Valencia-Flores et al., 2004). Chronic obesity in rats have also shown that 
hypoxic conditions do not contribute to obesity related PH but are related to increased 




4.8 Hypoxia induced PH in lean and obese female mice 
 
Lean and obese female B6 mice were exposed to hypoxia (10% oxygen) for 5 weeks. 
Obese female mice gained significant higher body mass index than their lean counterparts 
(Fig. 28). Similar to male mice, female mice were subjected to 5 weeks long hypoxia 
exposure. BMI of lean was fully unaffected due to hypoxia, but slight reduction of BMI 
was visible in obese mice. Echocardiographic measurements were done at the same time 
periods of 3 and 5 weeks, and hemodynamic measurements at 5 weeks after hypoxia 
exposure.  
 
A readily apparent PH was established at 3 weeks of hypoxia exposure in both lean and 
obese female mice. This was evident by significant increase in RVID and RVWT and 
decrease in TAPSE and PAAT/PAET. These conditions were stable until 5 weeks of 
hypoxia continuation in both of the groups. Hemodynamic measurements were done after 5 
weeks of normoxia or hypoxia treatment. SAP was similar in all the groups. Lean and 
obese female mice had elevated RVSP and Fulton's index under hypoxic condition, but no 
differences between these two groups were observed.  
 
The levels of distal pulmonary arteries remodeling were evaluated similar to those of male 
mice. Increased medial wall thickness and muscularization was present in both lean and 
obese hypoxic female mice except medial wall thickness in hypoxic obese mice where no 
increase was observed. However, the obese females had a bit lesser degree of medial wall 
thickness. In contrast, the right ventricle structure and functions were a bit worse for obese 
female mice. RVID and RVWT were higher, PAAT/PAET and TAPSE were lower for 
obese females. Therefore, there was no convincing evidence that obesity further altered or 







Fig. 33: Scheme for the characterization of hypoxia induced PH in lean and obese B6 mice of both 
of the genders. TAPSE = tricuspid annular plane systolic excursion, PAAT = pulmonary artery 




4.9 Conclusion, limitations and future perspectives 
 
The study on male and female obesity in murine models of PH revealed important 
differences with regard to gender and animal model (MCT- versus chronic hypoxia-
induced PH). MCT presented a more severe form of PH with significantly higher 
remodeling and worsening of hemodynamic parameters in males, compared to the females. 
However, obesity was not found to be an important modulator of PH in males. Conversely, 
80 
 
obesity was found to be an important factor for the disease pathology in females. 
Interestingly, higher degree of inflammation was evident in obese animals of both male and 
female Zucker rats. On the other hand, hypoxia induced PH in obese male and female mice 
resulted in negligible differences between lean and obese or males and females. Therefore, 
in contrast to inflammatory-driven pathology (such as in MCT-model), obesity was not 
demonstrated as significant pathological factor for chronic hypoxia-induced PH. 
 
           
            
Fig. 34: Scheme for the characterization of obesity related pulmonary hypertension. The 




This study was not free of limitations. As an established protocol for MCT administration 
of 300-350 gm body weight in rats (Schermuly et al., 2005), same range of body weight 
was chosen to avoid any variance in the MCT model itself. This urged to administer MCT 
into rats which had relatively lesser BMI and gained the body weight during the 35 days 
experimental stint. Researchers exploit obesity induced over longer period (greater than 5 
months) to have more concrete results (Irwin et al., 2014; Khoo et al., 2012). Due to time 
and resource constraints, the study used only two animal models of PH namely, MCT 
model of PH in rats and hypoxia model of PH in mice.  
 
This study reserves the molecular pathway scrutiny for further elucidation of obesity 
related pathobiology in PH. Because of the complexity of PH as well as the variation of 
species in obesity effects, different species as well as new models of PH would provide 








Obesity and pulmonary hypertension (PH) are medical conditions, both characterized by 
augmented inflammation and oxidative stress. Some of the studies showed a possible 
correlation between obesity and PH. However, the exact role or contribution of obesity to 
the pathology of this pulmonary vascular disease is still unknown and needs further 
research. 
 
Animal experiments were conducted on monocrotaline (MCT) and hypoxia models of PH. 
Lean and obese Zucker rats or B6 mice of both gender were used for MCT or chronic 
hypoxia models, respectively. Lean and obese (male or female) Zucker rats or B6 mice 
were further divided into two groups, receiving either normal saline/normoxia exposure or 
MCT injection/hypoxia exposure for 5 weeks. Echocardiography, hemodynamic 
measurements and histology were performed to analyze various parameters, such as heart 
function and hypertrophy, hemodynamics, pulmonary vascular remodeling and lung 
inflammation. 
 
MCT injection resulted in the development of PH in both lean and obese male and female 
rats. Negligible differences in terms of PH severity were observed between lean and obese 
male rats at the end stage of the disease. Conversely, obese female rats developed more 
prominent and severe PH compared to their lean counterparts. On the other hand, no 
apparent differences were found between lean and obese mice and gender factor also 
appeared to have negligible influence in the context of chronic hypoxia-induced PH.  
 
As a conclusion, obesity is found to be important factor associated with altered 
inflammation. In addition, significant differences between genders existed in the MCT 
model with regard to the severity of this life-threatening pulmonary vascular disease. 







Adipositas und Pulmonale Hypertonie (PH) sind Erkrankungen, die beide durch vermehrte 
Inflammation und oxidativem Stress charakterisiert sind. Einige Studien zeigten eine 
mögliche Korrelation zwischen Adipositas und PH. Allerdings sind die exakten 
Auswirkungen der Fettleibigkeit auf die Pathologie dieser Lungengefäßerkrankung noch 
nicht bekannt und bedürfen weiterer Forschung. 
 
In dieser Arbeit wurden zwei verschiedene tierexperimentelle Modelle zur Nachahmung 
der PH verwendet. Das Monocrotalin (MCT)-Modell wurde in schlanken und fettleibigen 
Zucker Ratten beiderlei Geschlechts angewendet. In ebenfalls beiden Geschlechtern von 
C57Bl6 Mäusen wurde das Modell der chronischen Hypoxie verwendet. Beide Modelle 
hatten eine Laufzeit von 5 Wochen. Beide Kohorten (männlich und weiblich) wurden in 
zwei Gruppen aufgeteilt. Die schlanken und fettleibigen Zucker Ratten erhielten entweder 
die MCT-Injektion oder die Kochsalzlösung-Injektion. Die C57Bl6N-Mäuse wurden 
entweder unter normoxischen oder hypoxischen Bedingungen gehalten. 
Echokardiographie, hämodynamische Druckmessungen und histologische Untersuchungen 
wurden durchgeführt, um verschiedene Parameter, wie die Herzfunktion, 
Rechtsherzhypertrophie, vaskuläres Remodelling und inflammatorische Prozesse in der 
Lunge, zu analysieren. 
 
Die MCT-Injektion führte bei schlanken und fettleibigen männlichen und weiblichen 
Ratten zur Entwicklung einer PH. Es wurden unbedeutende Unterschiede in Bezug auf den 
Schweregrad der PH zwischen schlanken und übergewichtigen männlichen Ratten im 
Endstadium der Krankheit beobachtet. Im Gegensatz dazu entwickelten weibliche adipöse 
Ratten eine schwerere PH im Vergleich zu den schlanken Pendants. Bei der Induktion einer 
PH mittels chronischer Hypoxie wurden keine offensichtlichen Unterschiede zwischen 
schlanken und fettleibigen Mäusen beiden Geschlechts gefunden. 
 
Abschließend ist zu sagen, dass die Adipositas ein wichtiger Faktor in Verbindung mit 
einer veränderten Entzündungsreaktion ist. Im Hinblick des Schweregrades dieser 
lebensbedrohlichen Lungengefäßkrankheit bestehen darüber hinaus signifikante 
Unterschiede zwischen beiden Geschlechtern im MCT-Modell. Allerdings sind weitere 
Studien notwendig, um die Ergebnisse dieser Arbeit zu untermauern und die 
zugrundeliegenden Mechanismen im Detail zu verstehen. 
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7. List of abbreviations  
 
ALK-1 = activin receptor-like kinase 1 
Ang = angiotensinogen 
ANOVA = analysis of variance 
bFGF = basic fibroblast growth factor 
BMI = body mass index 
BMPR2 = bone morphogenetic protein receptor type II 
BSA = body surface area 
BSA = bovine serum albumin 
CAV1 = caveolin-1 
cc = cubic centimeter 
CD 68 = cluster of differentiation 68 
cGMP = cyclic guanosine monophosphate 
CI = cardiac index 
cm = centimeter 
CO = cardiac output 
CO2 = carbon dioxide 
COMPERA = Comparative, Prospective Registry of Newly Initiated Therapies for PH 
COPD = chronic obstructive pulmonary disease 
CRP = c reactive protein 
DAB = 3,3'-Diaminobenzidine 
EDTA = ethylenediaminetetraacetate 
ENG = endoglin 
eNOS = endothelial nitric oxide synthase 
F2 IsoPs = F2 isoprostanes 
Fig. = figure 
gm = gram 
H2O = hydrogen monoxide (water) 
H2O2 = hydrogen peroxide  
HCl = hydrogen chloride 
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HIV = human immuno-deficiency virus 
HOX = hypoxia 
HR = heart rate 
i.e. = id est (that is) 
IL-6 interleukin 6 
KCl = potassium chloride 
KCNK3 = Potassium channel subfamily K member 3 
Kg = kilogram 
KH2PO4 = potassium dihydrogen phosphate 
LA = left atrium 
LV = left ventricle 
LV+S = left ventricle plus septum 
m = meter 
MCP-1 = monocyte chemoattractant protein-1 
MCT = monocrotaline 
ml = milli liter 
mRNA = micro ribonucleic acid 
N2 = nitrogen 
Na2HPO4  = sodium hydrogen phosphate 
NaCl = sodium chloride 
NaOH = sodium hydroxide 
NOX = normoxia 
NS = normal saline 
O2 = oxygen 
OB = obese 
O
C = degree centigrade 
oxLDL = oxidized low density lipoprotein 
PA = pulmonary artery 
PAAT = Pulmonary artery acceleration time  
PACP = pulmonary artery capillary pressure 
PAET = pulmonary artery ejection time 
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PAH = pulmonary arterial hypertension 
PAWP = pulmonary artery wedge pressure 
PBS = phosphate buffer saline 
PDE5 = phosphodiesterase 5 
PDGF = platelet derived growth factor 
PH = pulmonary hypertension 
PPAR-β = peroxisome proliferator-activated receptors - beta 
PV = pulmonary vein 
PVRI = Pulmonary Vascular Research Institute 
RA = right atrium 
rpm = revolutions per minute 
RV = right ventricle 
RVID = right ventricle internal diameter 
RVSP = right ventricular systolic pressure 
RVWT = right ventricle free wall thickness 
SA node = sino-artrial node  
SAP = systemic arterial pressure 
SEM = standard error of mean 
SMAD9 = mothers against decapentaplegic homolog 9  
SU5416 =  3-[(2,4-dimethylpyrrol-5-yl) methylidenyl]-indolin-2-one 
SV = stroke volume 
TAPSE = tricuspid annular plane systolic excursion 
TGF-β = transforming growth factor - beta  
TNF-α = tumor necrosis factor-alpha 
VEGF = vascular endothelial growth factor 
VEGFR = vascular endothelial growth factor receptor 
vWF = von-Willebrand factor 
WHO = World Health Organization  
WT = wild type 
α-SMA = alpha smooth muscle actin 
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